[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 941
6. Sharma S, Iwasaki M, Kunieda C, Cao X, Ishihara J, Hamada G, Miyajima NT, Tsugane S, Le Marchand L: Development of a quantitative food frequency questionnaire for assessing food, nutrient, and heterocyclic aromatic amines intake in Japanese Brazilians for a colorectal adenoma case-control study. Int J Food Sci Nutr; 2009;60 Suppl 7:128-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a quantitative food frequency questionnaire for assessing food, nutrient, and heterocyclic aromatic amines intake in Japanese Brazilians for a colorectal adenoma case-control study.
  • PRIMARY OBJECTIVE: To develop of a quantitative food frequency questionnaire (QFFQ) to assess intake of specific foods, nutrients and heterocyclic aromatic amines (HAAs) in a case-control study of colorectal adenoma.
  • CONCLUSIONS: We have developed a QFFQ appropriate for Japanese Brazilians that will allow us to estimate HAA intake and will be used to examine our hypotheses related to foods, nutrients and HAAs, and diet-gene interactions in colorectal neoplasia in this population.
  • [MeSH-major] Adenoma. Amines / administration & dosage. Colorectal Neoplasms. Diet. Diet Surveys. Food Analysis. Polycyclic Hydrocarbons, Aromatic / administration & dosage

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381993.001).
  • [ISSN] 1465-3478
  • [Journal-full-title] International journal of food sciences and nutrition
  • [ISO-abbreviation] Int J Food Sci Nutr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R03 CA119682
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amines; 0 / Polycyclic Hydrocarbons, Aromatic
  •  go-up   go-down


7. Zhang W, Bauer M, Croner RS, Pelz JO, Lodygin D, Hermeking H, Stürzl M, Hohenberger W, Matzel KE: DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Dis Colon Rectum; 2007 Oct;50(10):1618-26; discussion 1626-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene.
  • PURPOSE: To investigate a potential mode of noninvasive screening for colorectal cancer, we evaluated the hypermethylation of the secreted frizzled-related protein-1 gene promoter in human stool DNA.
  • METHODS: In stool samples from 36 patients with colorectal neoplasia (7 adenoma, 29 colorectal cancer) and 17 healthy control subjects, isolated DNA was treated with sodium bisulfite and analyzed by methylation-specific polymerase chain reaction with primers specific for methylated or unmethylated promoter sequences of the secreted frizzled-related protein-1 gene.
  • RESULTS: Hypermethylation of the secreted frizzled-related protein-1 promoter was present in the stool DNA of patients with adenoma and colorectal cancer.
  • A sensitivity of 89 percent and specificity of 86 percent were achieved in the detection of colorectal neoplasia.
  • The difference in hypermethylation status of the secreted frizzled-related protein-1 promoter between the patients with colorectal neoplasia and the control group was statistically highly significant (P < 0.001).
  • Adenoma and early tumor Stage I (International Union Against Cancer) displayed both unmethylated and methylated secreted frizzled-related protein-1 promoter sequences, whereas advanced tumor stages showed only methylated secreted frizzled-related protein-1 (P = 0.05).
  • It has the potential of a clinically useful test for the early detection of colorectal cancer.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colorectal Neoplasms / metabolism. DNA Methylation. Feces. Intercellular Signaling Peptides and Proteins / metabolism. Membrane Proteins / metabolism


8. Lobach I, Carroll RJ, Spinka C, Gail MH, Chatterjee N: Haplotype-based regression analysis and inference of case-control studies with unphased genotypes and measurement errors in environmental exposures. Biometrics; 2008 Sep;64(3):673-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inferences with measurement error corrections are complicated by the fact that the Wald test often behaves poorly in the presence of large amounts of measurement error.
  • An application of our method is illustrated using a population-based case-control study of the association between calcium intake and the risk of colorectal adenoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biometrics. 2001 Sep;57(3):795-802 [11550930.001]
  • [Cites] Cancer Causes Control. 2002 Dec;13(10):937-46 [12588090.001]
  • [Cites] Am J Epidemiol. 2003 Jul 1;158(1):1-13 [12835280.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1316-29 [14631556.001]
  • [Cites] Genet Epidemiol. 2004 Nov;27(3):192-201 [15372619.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2181-6 [15598778.001]
  • [Cites] Genet Epidemiol. 2005 Sep;29(2):108-27 [16080203.001]
  • (PMID = 18047538.001).
  • [ISSN] 1541-0420
  • [Journal-full-title] Biometrics
  • [ISO-abbreviation] Biometrics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA057030; United States / NCI NIH HHS / CA / R25 CA090301; United States / NCI NIH HHS / CA / CA57030; United States / NCI NIH HHS / CA / R37 CA057030-20; United States / NCI NIH HHS / CA / R01 CA057030; United States / NCI NIH HHS / CA / CA90301; United States / NCI NIH HHS / CA / CA057030-20; United States / NCI NIH HHS / CA / R37 CA057030; United States / NIEHS NIH HHS / ES / P30 ES009106; United States / NIEHS NIH HHS / ES / P30-ES09106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium, Dietary
  • [Other-IDs] NLM/ NIHMS101403; NLM/ PMC2672569
  •  go-up   go-down


9. Oh K, Willett WC, Fuchs CS, Giovannucci E: Dietary marine n-3 fatty acids in relation to risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev; 2005 Apr;14(4):835-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary marine n-3 fatty acids in relation to risk of distal colorectal adenoma in women.
  • Epidemiologic studies of dietary marine n-3 fatty acids and risk of colorectal cancer have been inconsistent, and their relation to risk of colorectal adenoma has not been evaluated in detail.
  • We examined dietary marine n-3 fatty acids and the ratio of marine n-3 to total n-6 fatty acids (n-3/n-6 ratio) in relation to risk of adenoma of the distal colon or rectum among 34,451 U.S. women who were initially free of colorectal cancer or polyps, who completed a semiquantitative food frequency questionnaire in 1980, and who underwent endoscopy from 1980 to 1998.
  • We documented 1,719 distal colorectal adenoma cases (705 large adenomas, 897 small adenomas, 1,280 distal colon adenomas, and 505 rectal adenomas) during 18 years of follow-up.
  • Neither dietary marine n-3 fatty acids nor n-3/n-6 ratio were associated with risk of total distal colorectal adenoma after adjustment for age and established risk factors [multivariable relative risk (RR) for extreme quintiles of dietary marine n-3 fatty acids = 1.04; 95% confidence interval (95% CI), 0.84-1.27, P(trend) = 0.66; RR for extreme quintiles of n-3/n-6 ratio = 1.02; 95% CI, 0.83-1.25; P(trend) = 0.86].
  • Similarly, no significant associations were observed separately for distal colon or rectal adenoma.
  • However, higher intake of dietary marine n-3 fatty acids was nonsignificantly but suggestively inversely associated with large adenoma (RR, 0.74; 95% CI, 0.54-1.01; P(trend) = 0.16) but directly associated with small adenoma (RR, 1.36; 95% CI, 1.02-1.81; P(trend) = 0.09).
  • Our findings do not support the hypothesis that a higher intake of marine n-3 fatty acids or a higher n-3/n-6 ratio reduces the risk of distal colorectal adenoma but are suggestive that higher intake may reduce the progression of small adenomas to large adenomas.
  • [MeSH-major] Adenoma / prevention & control. Colorectal Neoplasms / prevention & control. Diet. Fatty Acids, Omega-3 / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):406-7 [16492940.001]
  • (PMID = 15824153.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 87969; United States / NCI NIH HHS / CA / CA55075
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0RBV727H71 / alpha-Linolenic Acid
  •  go-up   go-down


10. Fracchia M, Galatola G, Sarotto I, Guraldo V, Perona M, Pera A, Risio M: Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas. Dig Liver Dis; 2005 Jul;37(7):509-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas.
  • BACKGROUND: Deoxycholic acid induced programmed cell death and an imbalance with cell proliferation may favour colorectal tumourigenesis according to 'in vitro' studies, but information is lacking on the relationships occurring 'in vivo' in humans.
  • METHODS: In 10 patients with colorectal adenomas, we measured fasting serum levels of bile acids; and, in normal colonic mucosa, programmed cell death by the TUNEL technique and cell proliferation by immunohistochemical staining with anti-Ki67.
  • [MeSH-major] Adenoma / blood. Apoptosis / drug effects. Bile Acids and Salts / blood. Cell Proliferation / drug effects. Colorectal Neoplasms / blood. Deoxycholic Acid / blood. Deoxycholic Acid / pharmacology. Intestinal Mucosa / cytology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975538.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Bile Acids and Salts; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 005990WHZZ / Deoxycholic Acid
  •  go-up   go-down


11. Heijink DM, Kleibeuker JH, Jalving M, Boersma-van Ek W, Koornstra JJ, Wesseling J, de Jong S: Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas. Cell Oncol; 2007;29(5):409-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas.
  • METHODS: The aim of this study was to investigate basic expression of caspase-8 and cFLIP in normal colorectal epithelium (n=20), colorectal adenomas (n=66) and colorectal carcinomas (n=44) using immunohistochemistry performed on both sporadic and Hereditary Non-Polyposis Colorectal Cancer (HNPCC or Lynch syndrome)-associated adenomas and carcinomas.
  • Expression of caspase-8 in colorectal adenomas and carcinomas was increased when compared to normal colon tissue (P=0.02).
  • Immunohistochemistry revealed an upregulation of cFLIP in colorectal carcinomas in comparison to normal epithelium and colorectal adenomas (P<0.001).
  • A large variation in the caspase-8/cFLIP ratio was observed between the individual adenomas and carcinomas.
  • CONCLUSION: Caspase-8 and cFLIP are upregulated during colorectal carcinogenesis.
  • Upregulation of caspase-8 and/or downregulation of cFLIP may be interesting approaches to maximize TRAIL sensitivity in colorectal neoplasms.
  • [MeSH-major] Adenoma / enzymology. CASP8 and FADD-Like Apoptosis Regulating Protein / metabolism. Caspase 8 / biosynthesis. Colorectal Neoplasms, Hereditary Nonpolyposis / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726263.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; EC 3.4.22.- / Caspase 8
  • [Other-IDs] NLM/ PMC4617989
  •  go-up   go-down


12. Pufulete M, Al-Ghnaniem R, Khushal A, Appleby P, Harris N, Gout S, Emery PW, Sanders TA: Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma. Gut; 2005 May;54(5):648-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of folic acid supplementation on genomic DNA methylation in patients with colorectal adenoma.
  • BACKGROUND AND AIMS: A low dietary folate intake can cause genomic DNA hypomethylation and may increase the risk of colorectal neoplasia.
  • The hypothesis that folic acid supplementation increases DNA methylation in leucocytes and colorectal mucosa was tested in 31 patients with histologically confirmed colorectal adenoma using a randomised, double blind, placebo controlled, parallel design.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. DNA Methylation / drug effects. Dietary Supplements. Folic Acid / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1994 Dec;37(12):1340-1 [7995171.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29318-23 [10884384.001]
  • [Cites] Eur J Cancer Prev. 1994 Nov;3(6):473-9 [7858479.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):265-73 [7707417.001]
  • [Cites] Am J Clin Nutr. 2000 Oct;72(4):998-1003 [11010943.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5434-40 [11034085.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):184-95 [11197251.001]
  • [Cites] Am J Clin Nutr. 2001 Mar;73(3):613-21 [11237940.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] Gut. 2002 Apr;50(4):520-4 [11889073.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5606-11 [11929966.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1376-87 [11984524.001]
  • [Cites] Pharmacogenetics. 2002 Jun;12(4):339-42 [12042673.001]
  • [Cites] Br J Nutr. 2002 Apr;87(4):383-90 [12064348.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6442-6 [12438232.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1611-21 [12496052.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):743-8 [12576444.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1043-5 [12651596.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1361-71 [12651628.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1240-8 [12730865.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3133-7 [12810640.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):297-304 [12893078.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5 [14676107.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):1-8 [15017625.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2B):649-54 [15161007.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1507-15 [15016659.001]
  • [Cites] J Nutr Biochem. 2004 Sep;15(9):554-60 [15350988.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] Science. 1985 Apr 12;228(4696):187-90 [2579435.001]
  • [Cites] Br J Cancer. 1992 May;65(5):667-72 [1586594.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Jun 30;193(3):1184-90 [8323540.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(9):549-54 [8392076.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] Dis Colon Rectum. 1995 Jan;38(1):64-7; discussion 67-8 [7813348.001]
  • [Cites] Nat Genet. 1995 May;10(1):111-3 [7647779.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):709-14 [8672986.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4862-4 [8895734.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1098-102 [9067278.001]
  • [Cites] Int J Cancer. 1997 Mar 17;70(6):644-8 [9096643.001]
  • [Cites] J Nutr. 1998 Jul;128(7):1204-12 [9649607.001]
  • [Cites] Ann Intern Med. 1998 Oct 1;129(7):517-24 [9758570.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1917-22 [10206314.001]
  • [Cites] Clin Nutr. 1998 Apr;17(2):45-9 [10205316.001]
  • [Cites] Ann Intern Med. 1999 Sep 7;131(5):331-9 [10475885.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):825-9 [10498402.001]
  • [Cites] Genet Epidemiol. 1999 Nov;17(4):298-309 [10520212.001]
  • [Cites] Cancer Lett. 2000 Apr 14;151(2):181-6 [10738112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Aug;8(8):659-68 [10744125.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jul;9(7):657-63 [10919734.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):849-53 [10952104.001]
  • [CommentIn] Gut. 2005 May;54(5):579-81 [15831897.001]
  • (PMID = 15831910.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid
  • [Other-IDs] NLM/ PMC1774481
  •  go-up   go-down


13. Ding XW, Yan JJ, An P, Lü P, Luo HS: Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines. World J Gastroenterol; 2007 Feb 28;13(8):1257-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines.
  • AIM: To study the expression of ether à go-go (Eag1) potassium channel in colorectal cancer and the relation-ship between their expression and clinico-pathological features.
  • METHODS: The expression levels of Eag1 protein were determined in 76 cancer tissues with paired non-cancerous matched tissues as well as 9 colorectal adenoma tissues by immunohistochemistry.
  • Eag1 mRNA expression was detected in 13 colorectal cancer tissues with paired non-cancerous matched tissues and 4 colorectal adenoma tissues as well as two colorectal cancer cell lines (LoVo and HT-29) by reverse transcription PCR.
  • RESULTS: The frequency of positive expression of Eag1 protein was 76.3% (58/76) and Eag1 mRNA was 76.9% (10/13) in colorectal cancer tissue.
  • Eag1 protein and mRNA were negative in normal colorectal tissue, and absolutely negative in colorectal adenomas except that one case was positively stained for Eag1 protein.
  • CONCLUSION: Eag1 protein and mRNA are aberrantly expressed in colorectal cancer and occasionally expressed in colorectal adenoma.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colorectal Neoplasms / metabolism. Ether-A-Go-Go Potassium Channels / metabolism. Gene Expression Regulation, Neoplastic


1
Advertisement
4. Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K: Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell; 2008 May;13(5):407-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, we show here that PROX1 promotes dysplasia in colonic adenomas and colorectal cancer progression.
  • PROX1 expression marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenomas in Apc(min/+) mice, while its transgenic overexpression promotes colorectal tumorigenesis.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Homeodomain Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Carcinoma in Situ / genetics. Cell Line, Tumor. Colorectal Neoplasms / genetics. Disease Progression. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Phenotype. beta Catenin / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455124.001).
  • [ISSN] 1878-3686
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] eng
  • [Grant] United Kingdom / Worldwide Cancer Research / / 09-0791; United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 0 / prospero-related homeobox 1 protein
  •  go-up   go-down


15. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge M, Armitage N, Shepherd V, Popat S, Houlston RS, United Kingdom Colorectal Adenoma Prevention Consortium: Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence. Clin Cancer Res; 2006 Nov 1;12(21):6585-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
  • Functional polymorphisms of UGT1A6 (T181A and R184S) and CYP2C9 (R144C and I359L) have been reported to modify the protective effect of aspirin on colorectal adenoma risk.
  • We aimed to further investigate the effect of these genetic variants on the development of colorectal neoplasia.
  • EXPERIMENTAL DESIGN: We examined the relationship between UGT1A6 and CYP2C9 genotype and colorectal adenoma recurrence in 546 patients participating in a randomized placebo-controlled aspirin intervention trial.
  • RESULTS: Although colorectal adenoma recurrence was not significantly influenced by CYP2C9 genotype, carriers of variant UGT1A6 alleles were at significantly reduced risk of colorectal neoplasia recurrence [relative risk (RR), 0.68; 95% confidence interval (95% CI), 0.52-0.89].
  • CONCLUSIONS: These findings confirm that UGT1A6 variants influence colorectal carcinogenesis independent of aspirin intake and suggest that they may have clinical value in secondary prevention programs for patients diagnosed with colorectal adenoma.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Genetic Predisposition to Disease. Glucuronosyltransferase / genetics. Neoplasm Recurrence, Local / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085674.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; EC 2.4.1.- / UDP-glucuronosyltransferase, UGT1A6; EC 2.4.1.17 / Glucuronosyltransferase; R16CO5Y76E / Aspirin
  •  go-up   go-down


16. Zhu XL, Liang L, Ding YQ: [Galectin-1 expression in human colorectal carcinoma and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep;27(9):1331-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Galectin-1 expression in human colorectal carcinoma and its clinical significance].
  • OBJECTIVE: To investigate the correlation between galectin-1 expression and the biological behaviors of human colorectal carcinoma.
  • METHODS: SP immunohistochemistry was used to detect the expression of galectin-1 in 158 paraffin-embedded specimens including 30 normal mucosa, 25 adenoma, 65 colorectal carcinoma and 38 metastatic tumor specimens.
  • Real-time RT-PCR was used to detect galectin-1 mRNA expression in 32 fresh specimens of colorectal carcinoma and normal mucosa.
  • RESULTS: The positive expression level of galectin-1 was significantly different between normal mucosa, adenoma, colorectal carcinomas and metastatic tumors, with positivity rate of 0, 8%, 66% and 86%, respectively (P<0.05).
  • Galectin-1 expression in moderately or well differentiated colorectal carcinomas was significantly lower than that in poorly differentiated ones (P=0.031), and its expression in invasive carcinomas was significantly higher than that in non-invasive carcinomas (P=0.000).
  • Galectin-1 expression in colorectal carcinomas was significantly related with lymph node metastasis (P=0.004).
  • In poorly differentiated colorectal carcinomas, the expression of galectin-1 mRNA was about 2.27 times that in moderately or well differentiated colorectal carcinomas (P=0.00); galectin-1 mRNA expression in invasive carcinoma was 1.98 times that in non-invasive carcinoma (P=0.002).
  • CONCLUSION: Galectin-1 can be involved in the development and progression of colorectal carcinoma, and may relate to the infiltration, differentiation and lymph node metastasis of colorectal carcinoma.
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Galectin 1 / genetics. Galectin 1 / metabolism. Gene Expression Regulation, Neoplastic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884770.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Galectin 1; 0 / RNA, Messenger
  •  go-up   go-down


17. Dai Q, Shrubsole MJ, Ness RM, Schlundt D, Cai Q, Smalley WE, Li M, Shyr Y, Zheng W: The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. Am J Clin Nutr; 2007 Sep;86(3):743-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk.
  • BACKGROUND: Mean magnesium intake in the US population does not differ from that in East Asian populations with traditionally low risks of colorectal cancer and other chronic diseases, but the ratio of calcium to magnesium (Ca:Mg) intake is much higher in the US population.
  • OBJECTIVE: We aimed to test whether the association of colorectal polyps with intake of calcium, magnesium, or both and Thr1482Ile polymorphism in the TRPM7 gene is modified by the Ca:Mg intake.
  • DESIGN: Included in the study were a total of 688 adenoma cases, 210 hyperplastic polyp cases, and 1306 polyp-free controls from the Tennessee Colorectal Polyp Study.
  • RESULTS: We found that total magnesium consumption was linked to a significantly lower risk of colorectal adenoma, particularly in those subjects with a low Ca:Mg intake.
  • The subjects who carried >or=1 1482Ile allele and who consumed diets with a high Ca:Mg intake were at a higher risk of adenoma (odds ratio: 1.60; 95% CI: 1.12, 2.29) and hyperplastic polyps (odds ratio: 1.85; 95% CI: 1.09, 3.14) than were the subjects who did not carry the polymorphism.
  • CONCLUSION: These findings, if confirmed, may provide a new avenue for the personalized prevention of magnesium deficiency and, thus, colorectal cancer.

  • MedlinePlus Health Information. consumer health - Calcium.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):163-8 [9488592.001]
  • [Cites] Eur J Clin Nutr. 2004 Dec;58(12):1604-11 [15199383.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 24;1739(1):26-32 [15607114.001]
  • [Cites] J Am Soc Nephrol. 2005 Jan;16(1):15-26 [15574510.001]
  • [Cites] JAMA. 2005 Jan 5;293(1):86-9 [15632340.001]
  • [Cites] Curr Mol Med. 2005 May;5(3):309-22 [15892650.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):137-44 [15880532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11510-5 [16051700.001]
  • [Cites] Pflugers Arch. 2005 Oct;451(1):228-34 [16075242.001]
  • [Cites] Public Health Nutr. 2005 Dec;8(8):1293-9 [16372925.001]
  • [Cites] Am J Epidemiol. 2006 Feb 1;163(3):232-5 [16319289.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):129-36 [17227996.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):2006-9 [17035414.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Arch Biochem Biophys. 2007 Feb 1;458(1):24-32 [16564020.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):510-3 [17285123.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1151-8 [10904088.001]
  • [Cites] Histopathology. 2000 Oct;37(4):295-301 [11012735.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):239-297 [11152759.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1307-13 [11535705.001]
  • [Cites] Annu Rev Physiol. 2002;64:529-49 [11826278.001]
  • [Cites] Eur J Nutr. 2002 Oct;41(5):197-202 [12395213.001]
  • [Cites] Int J Epidemiol. 2003 Feb;32(1):1-22 [12689998.001]
  • [Cites] J Womens Health (Larchmt). 2003 Mar;12(2):173-82 [12737716.001]
  • [Cites] Cell. 2003 Jul 25;114(2):191-200 [12887921.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] JAMA. 2003 Dec 10;290(22):2959-67 [14665657.001]
  • [Cites] Diabetes Care. 2004 Jan;27(1):134-40 [14693979.001]
  • [Cites] J Am Coll Nutr. 2004 Feb;23(1):63-70 [14963055.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2003 Dec;49(8):1295-304 [14984001.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2894-9 [14976260.001]
  • [Cites] Adv Data. 2004 Apr 27;(341):1-5 [15114720.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 7;96(13):1015-22 [15240785.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 Nov;(53):175-9 [119916.001]
  • [Cites] J Clin Endocrinol Metab. 1978 Oct;47(4):800-6 [263326.001]
  • [Cites] Am Heart J. 1984 Jul;108(1):188-93 [6375330.001]
  • [Cites] Magnes Trace Elem. 1990;9(3):143-51 [2248695.001]
  • [Cites] J Nutr. 1991 Jan;121(1):13-23 [1992050.001]
  • [Cites] J Clin Epidemiol. 1991;44(6):571-8 [2037862.001]
  • [Cites] Annu Rev Physiol. 1991;53:259-71 [2042962.001]
  • [Cites] Am J Clin Nutr. 1992 May;55(5):1018-23 [1315120.001]
  • [Cites] Am J Epidemiol. 1994 Jan 1;139(1):16-29 [8296771.001]
  • [Cites] Br J Cancer. 1996 Jul;74(1):145-51 [8679449.001]
  • [Cites] Epidemiology. 1996 May;7(3):264-8 [8728439.001]
  • [Cites] Epidemiology. 1996 Nov;7(6):590-7 [8899384.001]
  • [Cites] Am J Clin Nutr. 1997 Nov;66(5):1172-7 [9356535.001]
  • [Cites] Am J Clin Nutr. 1964 Jun;14:242-90 [14168977.001]
  • (PMID = 17823441.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / R01 CA072784; United States / NCI NIH HHS / CA / R01 CA072784-05; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / R01 CA97386; United States / NCI NIH HHS / CA / CA072784-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium, Dietary; 0 / TRPM Cation Channels; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / TRPM7 protein, human; I38ZP9992A / Magnesium
  • [Other-IDs] NLM/ NIHMS33891; NLM/ PMC2082111
  •  go-up   go-down


18. Borda Martín A, Martínez-Peñuela JM, Muñoz-Navas M, Borda Celaya F, Jiménez Pérez J, Carretero Ribón C: [Do metachronous colorectal adenomas show proximal shift?]. Gastroenterol Hepatol; 2010 Jun-Jul;33(6):419-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Do metachronous colorectal adenomas show proximal shift?].
  • [Transliterated title] ¿Presentan un desplazamiento hacia segmentos más proximales los adenomas metacrónicos en el cáncer colorrectal?
  • OBJECTIVE: To study the possibility of shift toward more proximal sites in colorectal cancer (CRC) after resection of tumors and synchronous lesions.
  • The localization of metachronous adenomas was compared with that of synchronous lesions overall and by sex, tumoral size and the number of synchronous lesions.
  • The frequency of exclusively proximal localization in first-, second- and third-generation metachronous adenomas was compared with that of synchronous adenomas.
  • RESULTS: A total of 54.5% of patients with CRC had synchronous adenomas.
  • After a median follow-up of 48 months, with 2.74+/-1.47 colonoscopies/case, 42.4% developed metachronous adenomas, 16.8% second-generation adenomas and 7.3% third-generation lesions.
  • Proximal shift was found in metachronous adenomas in both sexes, independently of tumoral size and the number of initial lesions.
  • The frequency of exclusively proximal localization in adenomas was 21.2% in synchronous lesions, 39.5% in first-generation metachronous adenomas (p=0.0001; OR=2.46 [1.50-3.95]), 42.6% in second-generation metachronous adenomas (p=0.0008; OR=2.77 [1.44-5.31]) and 39.3% in third-generation metachronous lesions (p=0.0003; OR=2.41 [0.97-5.93]).
  • CONCLUSIONS: We found a high incidence of synchronous and metachronous adenomas.
  • Metachronous adenomas showed a proximal shift, independently of sex, tumoral size and the number of synchronous lesions.
  • This tendency was maintained in successive generations of metachronous adenomas, thus demonstrating the need to perform complete colonoscopies throughout the postoperative follow-up period.
  • [MeSH-major] Adenoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20374971.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


19. Durno CA, Holter S, Sherman PM, Gallinger S: The gastrointestinal phenotype of germline biallelic mismatch repair gene mutations. Am J Gastroenterol; 2010 Nov;105(11):2449-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to characterize patients with GI small bowel and/or colorectal cancers (CRCs) who have germline biallelic MMR mutations.
  • Among the 29 patients with CRCs, the mean age of first cancer diagnosis was 16.4 years (range: 5-28).
  • More than one-third of patients had multiple colorectal adenomas (>10 polyps).
  • Six individuals with biallelic MMR gene mutations have been reported with small bowel adenocarcinoma (mean age 20 years (range: 11-41)).
  • CONCLUSIONS: Biallelic MMR mutations are an underrecognized cause of small bowel and colonic cancers in children and young adults.
  • [MeSH-major] Alleles. Colorectal Neoplasms / genetics. DNA Mismatch Repair. Genetic Predisposition to Disease. Germ-Line Mutation. Intestinal Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA Mutational Analysis. Databases, Factual. Humans. Intestine, Small. Microsatellite Instability. Phenotype. Registries

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531397.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Holt PR, Kozuch P, Mewar S: Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. Best Pract Res Clin Gastroenterol; 2009;23(6):889-907
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer is one of the commonest tumours in the Westernized world affecting mainly the elderly.
  • Effective screening permits discovery of colorectal cancer at an early highly treatable stage and allows for detection and removal of premalignant colorectal adenomas.
  • Screening methods that focus on cancer detection use fecal assays for the presence of blood or altered DNA, those for detection of adenomas (and early cancer) use endoscopic or computerised radiologic techniques.
  • Broad use of screening methods has lowered colorectal cancer development by about 50%.
  • Since 1996 the chemotherapeutic armamentarium for metastatic colorectal cancer has grown beyond 5-fluorouracil to include an oral 5-fluorouracil prodrug, capecitabine as well as irinotecan and oxaliplatin.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):784-8 [14697260.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Gut. 2004 Feb;53(2):284-90 [14724165.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27 [15000146.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):665-73 [15054679.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):324-30 [15242680.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3545-51 [15908665.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jul;314(1):1-8 [15805430.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2696-704 [15987918.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4866-75 [15939922.001]
  • [Cites] Mech Ageing Dev. 2005 Sep;126(9):987-1002 [15893363.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2297-303 [16140008.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1163-70 [16230070.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3523-9 [18640933.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):532-5 [18628760.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8671-8 [16314627.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):255-62 [16454827.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):189-93 [16492904.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):969-75 [16552438.001]
  • [Cites] JAMA. 2006 May 24;295(20):2357-65 [16720821.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):816-24 [16741639.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4085-91 [16943526.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):77-83 [16538491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2418-21 [17164364.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):15-22 [17086168.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1683-9 [17188959.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):129-36 [17227996.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):361-4 [17339621.001]
  • [Cites] Cancer Detect Prev. 2007;31(1):3-11 [17289293.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):585-92 [17239930.001]
  • [Cites] Oncologist. 2007 Mar;12(3):312-9 [17405895.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):604-10 [17160571.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] JAMA. 2007 Aug 15;298(7):754-64 [17699009.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3644-8 [17704414.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1745-52 [17855692.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4224-30 [17548839.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4217-23 [17548840.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] Gut. 2007 Nov;56(11):1585-9 [17591622.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4779-86 [17947725.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5390-6 [18048820.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11594-600 [18089788.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):29-38 [18022173.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1027-35 [18319413.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4097-106 [11689577.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):1931-8 [11932894.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):126-30 [11943888.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):759-66 [12035031.001]
  • [Cites] World J Gastroenterol. 2008 Jul 28;14(28):4429-33 [18680219.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Sep;67(3):255-62 [18400508.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1207-17 [18799557.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1046-9 [18797465.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8541-6 [18922929.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5326-34 [18854571.001]
  • [Cites] Br J Cancer. 2008 Dec 16;99(12):1991-2000 [19034277.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):196-203 [19124498.001]
  • [Cites] Gut. 2009 Feb;58(2):241-8 [18852257.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2651-7 [12039926.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2413S-2418S [12163703.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3478-83 [12177109.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):603-12 [12353948.001]
  • [Cites] Mech Ageing Dev. 2002 Nov;123(12):1543-52 [12470892.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):600-7 [12612897.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):879-80 [12621130.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62 [12917207.001]
  • [Cites] J Clin Invest. 2003 Nov;112(9):1351-60 [14597761.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):32-8 [18841250.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):5-16 [18922882.001]
  • [Cites] Br J Cancer. 2009 Feb 24;100(4):611-6 [19209175.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):267-76 [19211442.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):256-66 [19211452.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):741-54 [19166855.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104(3):739-50 [19240699.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 May;63(6):1017-22 [18781300.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 May;70(2):134-44 [19111473.001]
  • [Cites] Cancer. 2009 May 1;115(9):1967-76 [19235249.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3109-16 [19451431.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):364-71 [19235181.001]
  • [Cites] Gut. 2010 Jan;59(1):62-8 [19671542.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):136-47 [10623704.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1211-4 [10770302.001]
  • [Cites] Eur J Cancer Prev. 1999 Dec;8 Suppl 1:S73-86 [10772421.001]
  • [Cites] Curr Top Microbiol Immunol. 2000;249:101-18 [10802941.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8403-8 [10900004.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1081-90 [11036286.001]
  • [Cites] Lancet. 2000 Sep 16;356(9234):968-74 [11041397.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1264-6 [11504772.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):438-47; discussion 447-50 [15319715.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6919-23 [15466182.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1219-28 [15464182.001]
  • [Cites] Cancer. 1967 Sep;20(9):1520-61 [6038396.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):179-86 [4018911.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1559-65 [2443619.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2373-7 [3179952.001]
  • [Cites] Gastroenterology. 1988 Dec;95(6):1556-63 [3181679.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1407-18 [2476530.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):653-7 [1736103.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 21;84(20):1572-5 [1404450.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Arch Intern Med. 1995 Sep 11;155(16):1741-8 [7654107.001]
  • [Cites] Int J Colorectal Dis. 1996;11(1):45-8 [8919342.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):858-64 [9307184.001]
  • [Cites] Br J Surg. 1998 Jul;85(7):897-901 [9692559.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Ann Pharmacother. 2005 Jan;39(1):128-35 [15590869.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):390-4 [15667497.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):150-8 [15704049.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Dig Dis Sci. 2005 Nov;50(11):2147-52 [16240230.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):428-32 [17466484.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1443-51 [18349394.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Apr;27(8):697-712 [18248653.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • [Cites] Anticancer Drugs. 2008 Jun;19(5):447-64 [18418212.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2006-12 [18421053.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2311-9 [18390971.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4465-78 [18519710.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):82-90 [18482589.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):176-84 [18614739.001]
  • (PMID = 19942166.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000043; United States / NCRR NIH HHS / RR / UL1RR024143; United States / NCRR NIH HHS / RR / UL1 RR024143; United States / NCI NIH HHS / CA / U54CA100926; United States / NCI NIH HHS / CA / U54 CA100926
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 163
  • [Other-IDs] NLM/ NIHMS160270; NLM/ PMC3742312
  •  go-up   go-down


21. Pinsky PF, Fleshman J, Mutch M, Rall C, Charabaty A, Seligson D, Dry S, Umar A, Schoen RE: One year recurrence of aberrant crypt foci. Cancer Prev Res (Phila); 2010 Jul;3(7):839-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant crypt foci (ACF) are putative precursors of colorectal adenomas and have been postulated as a potential biomarker for colorectal cancer.
  • Subjects enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial were recruited for a study of ACF.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 AACR.
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Gastrointest Endosc. 2009 Aug;70(2):322-30 [19539919.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):633-9 [15239144.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Feb;20(2):173-81 [15683417.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):271-8 [15765447.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 May;5(5):526-33 [17433788.001]
  • [Cites] Gastrointest Endosc. 2008 Jun;67(7):1097-102 [18178205.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jan;7(1):86-92 [18829395.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):4-8 [19138929.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):21-31 [19138933.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 May;7(5):568-74 [19418605.001]
  • [Cites] Cancer Causes Control. 2009 Jul;20(5):653-61 [19067190.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1524-9 [12094877.001]
  • (PMID = 20570885.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS195702; NLM/ PMC2900400
  •  go-up   go-down


22. Rubio CA: Serrated neoplasias and de novo carcinomas in ulcerative colitis: a histological study in colectomy specimens. J Gastroenterol Hepatol; 2007 Jul;22(7):1024-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated neoplasias and de novo carcinomas in ulcerative colitis: a histological study in colectomy specimens.
  • BACKGROUND AND AIM: Cancer in ulcerative colitis (UC) originates in dysplastic crypts, adenomatous growths (UCAG), and UC-associated adenomas (UCAD).
  • The aim of the present study was to compare the histological phenotypes between UCAG, UCAD, and sporadic colorectal adenomas in non-colitics (non-UCAD), as well as between UC-associated carcinomas (UCC) and carcinomas in non-colitic patients (non-UCC).
  • Six UCC (5.6%) were de novo carcinomas.
  • This is the first study reporting the occurrence of serrated and microtubular UCAG and of de novo carcinomas in UC.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Colectomy. Colitis, Ulcerative / pathology. Colitis, Ulcerative / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery


23. Maaser K, Grabowski P, Oezdem Y, Krahn A, Heine B, Stein H, Buhr H, Zeitz M, Scherübl H: Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread. Clin Cancer Res; 2005 Mar 1;11(5):1751-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread.
  • In Unio Internationale Contra Cancrum (UICC) III colorectal cancers, a high level of PBR overexpression correlates with poor prognosis.
  • However, little is known about the role of PBR in the development and progression of colorectal cancer.
  • This study addresses the up-regulation of PBR during colorectal carcinogenesis and tumor spread.
  • One hundred sixteen consecutive patients undergoing surgery for colorectal cancer with either regional (59 patients) or distant metastases (57 patients) were followed-up for 5 years or until death.
  • UICC stage III patients with colorectal primaries highly overexpressing PBR developed metastases significantly more often than patients with low PBR overexpression in their primary carcinoma.
  • In 54 of the 116 patients adenomas and/or metastases and/or recurrences were available to be studied for PBR up-regulation during colorectal carcinogenesis and tumor spread.
  • PBR was found to be overexpressed in 86% of early and late adenomas.
  • The extent of PBR protein overexpression was equivalent in colorectal adenomas and carcinomas but slightly increased in metastases.
  • These data suggest a functional role of PBR during colorectal carcinogenesis and tumor spread.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Carcinoma / genetics. Carcinoma / pathology. Cell Transformation, Neoplastic / genetics. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Neoplasm Metastasis. Receptors, GABA / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2005 Sep 1;11(17):6408
  • (PMID = 15755996.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, GABA; 0 / TSPO protein, human
  •  go-up   go-down


24. Su Y, Shrubsole MJ, Ness RM, Cai Q, Kataoka N, Washington K, Zheng W: Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev; 2006 Sep;15(9):1719-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays.
  • OBJECTIVES: In this study, we evaluated the validity and reliability of using TMA to assess biomarkers in colorectal adenomas.
  • METHODS: Sixty-three consecutive patients with colorectal adenomas were recruited in this study.
  • Two TMA blocks were constructed using four punches from each adenoma (one periphery, one deep, and two middle zones).
  • RESULTS: Colorectal adenoma exhibited zonal, heterogeneous expression patterns for all five markers.
  • CONCLUSION: Our study indicates that TMA can be used to reliably assess the expression levels of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in colorectal adenoma tissues.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985035.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / P50 CA95103; United States / NCI NIH HHS / CA / R01 CA97386
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / beta Catenin; 136601-57-5 / Cyclin D1; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


25. Berndt SI, Huang WY, Fallin MD, Helzlsouer KJ, Platz EA, Weissfeld JL, Church TR, Welch R, Chanock SJ, Hayes RB: Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma. Cancer Res; 2007 Feb 1;67(3):1395-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma.
  • Base excision repair (BER) corrects DNA damage caused by oxidative stress and low folate intake, which are putative risk factors for colorectal neoplasia.
  • To examine the relationship between genetic variation in BER genes and colorectal adenoma risk, we conducted a case-control study of 767 cases of advanced colorectal adenoma and 773 controls from the baseline screening exam of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  • Cases included participants diagnosed with advanced left-sided adenoma, and controls were subjects without evidence of a left-sided polyp by sigmoidoscopy, frequency-matched to cases on race and gender.
  • Twenty single nucleotide polymorphisms were genotyped in four BER genes (APEX1, PARP1, POLB, and XRCC1), and conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI) for the association with colorectal adenoma.
  • The APEX1 51H variant was associated with a borderline significant decreased risk of colorectal adenoma (OR, 0.66; 95% CI, 0.44-1.00), and the XRCC1 399Q variant was inversely associated with risk among Caucasians (OR, 0.80; 95% CI, 0.64-0.99).
  • Homozygotes at two PARP1 loci (A284A and IVS13+118G>A) were also associated with a decreased risk of colorectal adenoma compared with wild-type carriers (OR, 0.70; 95% CI, 0.49-0.98 for both), which was restricted to advanced adenomas displaying histologically aggressive characteristics (OR, 0.51; 95% CI, 0.33-0.78, P = 0.002 for PARP1 A284A).
  • This study suggests that polymorphisms in APEX1, XRCC1, and PARP1 may be associated with advanced colorectal adenoma.
  • [MeSH-major] Adenomyoma / epidemiology. Adenomyoma / genetics. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / genetics. DNA Repair / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283177.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


31. Ye C, Shrubsole MJ, Cai Q, Ness R, Grady WM, Smalley W, Cai H, Washington K, Zheng W: Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep; 2006 Aug;16(2):429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
  • CpG island methylation has been observed in aberrant crypt foci (ACF) and adenomas in the colon, implicating it in the earliest aspects of colon cancer formation.
  • In addition, some investigators have identified an age-related increase in DNA methylation of the ESR1 locus in the colon mucosa, suggesting that DNA methylation may be a pre-neoplastic change that increases the risk of colon adenomas and colon cancer.
  • The promoter methylation patterns of these genes were examined in rectal biopsies (mucosa samples) of 97 colorectal adenoma cases and 94 healthy controls using methylation-specific PCR (MSP) assays.
  • The frequency of CDKN2A/p16 promoter methylation was very rare in normal colorectal tissue with a frequency of approximately 2%.
  • The methylation status of these genes in rectal mucosa biopsies detected by MSP assays may not distinguish between patients with and without adenomas in the colon.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820927.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / P50 CA95103; United States / NCI NIH HHS / CA / R01CA97386
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


32. Jenkins PJ: Cancers associated with acromegaly. Neuroendocrinology; 2006;83(3-4):218-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More recently, it has become apparent that patients with acromegaly may also have an increased prevalence of colorectal adenomas and cancer.
  • This may be due to elevated IGF-I, which is implicated in the development of sporadic colorectal cancer, and environmental factors, such as the bile acid deoxycholic acid, the levels of which are also increased in acromegaly.
  • Large-scale epidemiological studies are required to clarify this issue.
  • [MeSH-major] Acromegaly / complications. Breast Neoplasms / etiology. Colorectal Neoplasms / etiology. Prostatic Neoplasms / etiology
  • [MeSH-minor] Adenoma / blood. Adenoma / epidemiology. Adenoma / etiology. Carcinoma / blood. Carcinoma / epidemiology. Carcinoma / etiology. Female. Human Growth Hormone / blood. Humans. Male


33. Moslehi R, Chatterjee N, Church TR, Chen J, Yeager M, Weissfeld J, Hein DW, Hayes RB: Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics; 2006 Sep;7(6):819-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma.
  • BACKGROUND: Cigarette use is associated with greater risk for colorectal adenoma, a colorectal cancer precursor.
  • Our interest is in the polymorphisms within the NAT1 and NAT2 genes that influence the tobacco-colorectal tumor relationship by impacting on the metabolic activation and detoxification of tobacco smoke-derived carcinogens.
  • METHODS: In the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, we compared NAT1 and NAT2 gene variant distributions for 772 cases with left-sided advanced adenoma and 777 gender and age-matched controls.
  • RESULTS: Risks for advanced colorectal adenoma were significantly increased among recent smokers (current smokers or those who quit less than 10 years ago) (odds ratio [OR] = 2.3, 95% confidence interval [CI]: 1.7-3.1) and among those who smoked more than 20 cigarettes per day (OR = 1.7, 95% CI: 1.3-2.2), compared with nonsmokers.
  • CONCLUSIONS: Our study indicated that NAT2 gene variants associated with a slow acetylator phenotype were more susceptible to the effects of tobacco smoking with respect to adenoma risk, providing leads for disease prevention.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16981843.001).
  • [ISSN] 1462-2416
  • [Journal-full-title] Pharmacogenomics
  • [ISO-abbreviation] Pharmacogenomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-34627; United States / NCI NIH HHS / CA / CA034627-21; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA034627; United States / NCI NIH HHS / CA / R01 CA034627-21
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


34. Hassan C, Zullo A, Winn S, Eramo A, Tomao S, Rossini FP, Morini S: The colorectal malignant polyp: scoping a dilemma. Dig Liver Dis; 2007 Jan;39(1):92-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The colorectal malignant polyp: scoping a dilemma.
  • Colorectal adenomas containing invasive carcinoma represent the majority of early colorectal cancers.
  • [MeSH-major] Adenomatous Polyps / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113842.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 80
  •  go-up   go-down


35. Ayanian JZ, Sequist TD, Zaslavsky AM, Johannes RS: Physician reminders to promote surveillance colonoscopy for colorectal adenomas: a randomized controlled trial. J Gen Intern Med; 2008 Jun;23(6):762-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician reminders to promote surveillance colonoscopy for colorectal adenomas: a randomized controlled trial.
  • BACKGROUND: Most colorectal cancers develop from adenomatous polyps.
  • PATIENTS: Seven hundred seventeen patients who had colorectal adenomas removed during 1995 through 2000 and no follow-up colonoscopy identified via automated review of electronic records through March, 2006.
  • MEASUREMENTS AND MAIN RESULTS: The use of colonoscopy and detection of new adenomas or cancer were assessed at 6 months by a blinded medical record review in all patients.
  • New adenomas or cancer were detected in 14 (3.9%) intervention patients and 6 (1.7%) control patients (P = 0.06), representing 42.4% and 37.5% of patients who underwent colonoscopy in each group, respectively.
  • CONCLUSIONS: Among patients with prior colorectal adenomas, physician reminders increased the use of surveillance colonoscopy, but better systems are needed to identify eligible patients (ClinicalTrials.gov ID number NCT00397969).
  • [MeSH-major] Adenomatous Polyps / diagnosis. Appointments and Schedules. Colonic Polyps / diagnosis. Colonoscopy / utilization. Colorectal Neoplasms / diagnosis. Reminder Systems

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):433-7 [10744815.001]
  • [Cites] Arch Intern Med. 2007 Mar 12;167(5):507-12 [17353500.001]
  • [Cites] Gut. 2001 Jun;48(6):812-5 [11358901.001]
  • [Cites] J Gen Intern Med. 2001 Aug;16(8):531-7 [11556929.001]
  • [Cites] Ann Intern Med. 2002 May 7;136(9):641-51 [11992299.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Am J Med. 2003 Aug 1;115(2):129-33 [12893399.001]
  • [Cites] Med Care Res Rev. 2003 Sep;60(3):294-331 [12971231.001]
  • [Cites] Arch Intern Med. 2003 Dec 8-22;163(22):2733-6 [14662627.001]
  • [Cites] Ann Intern Med. 2004 Aug 17;141(4):264-71 [15313742.001]
  • [Cites] Cancer. 2004 Sep 1;101(5 Suppl):1188-200 [15316914.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):861-7 [7870142.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):587-93 [10428195.001]
  • [Cites] J Am Med Inform Assoc. 2005 Jul-Aug;12(4):431-7 [15802479.001]
  • [Cites] J Am Med Inform Assoc. 2006 Jan-Feb;13(1):5-11 [16221941.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Arch Intern Med. 2006 Mar 27;166(6):675-81 [16567608.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Arch Intern Med. 2006 Jul 10;166(13):1374-9 [16832002.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):614-26 [16996358.001]
  • [Cites] Ann Intern Med. 2006 Nov 7;145(9):646-53 [17088577.001]
  • [Cites] Ann Intern Med. 2006 Nov 7;145(9):654-9 [17088578.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2237-43 [17101942.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2272-7 [17101947.001]
  • [Cites] Health Aff (Millwood). 2006 Nov-Dec;25(6):w496-507 [17035341.001]
  • [Cites] Ann Intern Med. 2007 Feb 20;146(4):270-7 [17310051.001]
  • [Cites] Prev Med. 2000 Oct;31(4):429-39 [11006069.001]
  • (PMID = 18386103.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00397969
  • [Grant] United States / NCI NIH HHS / CA / R21 CA112365; United States / NCI NIH HHS / CA / R21-CA112365
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2517870
  •  go-up   go-down


36. Hariri LP, Tumlinson AR, Besselsen DG, Utzinger U, Gerner EW, Barton JK: Endoscopic optical coherence tomography and laser-induced fluorescence spectroscopy in a murine colon cancer model. Lasers Surg Med; 2006 Apr;38(4):305-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: The diagnostic feasibility of optical coherence tomography (OCT) and laser-induced fluorescence (LIF) have been evaluated for human colorectal cancer.
  • This study applies these technologies to a murine model of colorectal adenoma.
  • One adenoma was histologically identified; OCT visualized mucosal thickening/abnormal mass development over the imaging timepoints.
  • CONCLUSIONS: These preliminary data indicate endoscopic OCT-LIF has the potential to identify colorectal adenomas in murine models.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16596657.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109385; United States / NCI NIH HHS / CA / CA083148; United States / NCI NIH HHS / CA / CA095060; United States / NCI NIH HHS / CA / CA109385
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


37. Noffsinger AE, Hart J: Serrated adenoma: a distinct form of non-polypoid colorectal neoplasia? Gastrointest Endosc Clin N Am; 2010 Jul;20(3):543-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated adenoma: a distinct form of non-polypoid colorectal neoplasia?
  • Until recently, 2 major forms of colorectal polyp were recognized: the adenoma and the hyperplastic polyp.
  • Adenomas were known to represent a precursor to colorectal cancer, whereas hyperplastic polyps were viewed as nonneoplastic, having no potential for progression to malignancy.
  • We now recognize, however, that the lesions diagnosed as hyperplastic polyps in the past represent a heterogeneous group of polyps, some of which truly are hyperplastic, and others that truly have a significant risk for transformation to colorectal cancer.
  • These polyps have a characteristic serrated architecture, and include not only hyperplastic polyps but also the recently recognized serrated adenomas.
  • Serrated adenomas occur in 2 forms: the traditional serrated adenoma, which is usually a polypoid lesion endoscopically, and the sessile serrated adenoma, a flat or slightly raised, usually right-sided lesion.
  • Serrated adenomas of both types show characteristic molecular alterations not commonly seen in traditional colorectal adenomas, and probably progress to colorectal cancer by means of a different pathway, the so-called serrated neoplasia pathway.
  • The morphologic features of serrated colorectal lesions, the molecular alterations that characterize them, and their role in colorectal cancer development are discussed.
  • [MeSH-major] Adenoma / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis
  • [MeSH-minor] Apoptosis. Colonic Polyps / diagnosis. Colonic Polyps / genetics. Colonic Polyps / pathology. CpG Islands / genetics. DNA Methylation. Disease Progression. Humans. Microsatellite Instability. Mutation. Phenotype. Polymorphism, Genetic. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. Receptor, EphB2 / genetics. Risk Assessment. ras Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20656251.001).
  • [ISSN] 1558-1950
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, EphB2; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


38. Yamaji Y, Okamoto M, Yoshida H, Kawabe T, Wada R, Mitsushima T, Omata M: The effect of body weight reduction on the incidence of colorectal adenoma. Am J Gastroenterol; 2008 Aug;103(8):2061-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of body weight reduction on the incidence of colorectal adenoma.
  • OBJECTIVES: Obesity is thought to be associated with colorectal cancer and adenoma.
  • We aimed to investigate the effect of body weight on the risk of colorectal adenoma both in cross-sectional and longitudinal analyses.
  • METHODS: This is a retrospective cohort study in a large-scale health appraisal institution in Japan.
  • The association with the prevalence of colorectal adenoma was evaluated according to the body mass index (BMI) at the initial examination.
  • The incidence of colorectal adenoma at the second colonoscopy was investigated according to the initial BMI and body weight changes during the year.
  • RESULTS: The prevalence of colorectal adenoma increased in relation to increases in the BMI: 15.4%, 20.6%, 22.7%, and 24.2%, respectively, in the first (BMI < 21.350), second (21.350 < or = BMI < 23.199), third (23.199 < or = BMI < 25.156), and fourth (25.156 < or = BMI) quartiles.
  • The incidence rates of colorectal adenoma after 1 yr also increased proportionally according to the initial BMI: Group Q1 (12.9%), Group Q2 (15.7%), Group Q3 (18.3%), and Group Q4 (19.0%).
  • CONCLUSIONS: Obesity was associated with the risk for colorectal adenoma, and body weight reduction was suggested to decrease this risk.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Obesity / complications. Weight Loss

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Weight Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796100.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Hisamuddin IM, Wehbi MA, Yang VW: Pharmacogenetics and diseases of the colon. Curr Opin Gastroenterol; 2007 Jan;23(1):60-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They affect the management of inflammatory bowel disease, colorectal cancer and the chemoprevention of colorectal adenoma by influencing the metabolism of their respective substrates, azathioprine/6-mercaptopurine, 5-fluorouracil and sulindac.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Genet. 1999 Jan;104(1):1-9 [10071185.001]
  • [Cites] Ann Intern Med. 1998 Nov 1;129(9):716-8 [9841604.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8357-62 [15623613.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):883-9 [10213225.001]
  • [Cites] Genomics. 1998 Aug 1;51(3):391-400 [9721209.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2239-47 [16181376.001]
  • [Cites] Ther Drug Monit. 2005 Oct;27(5):647-54 [16175140.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2366-9 [16214918.001]
  • [Cites] Invest New Drugs. 2005 Dec;23(6):523-32 [16267626.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):215-7 [16537192.001]
  • [Cites] Intern Med J. 2005 Oct;35(10):580-5 [16207256.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57 [16048561.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Gastroenterology. 2000 Apr;118(4):705-13 [10734022.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] Biochem Pharmacol. 2000 Jul 1;60(1):7-17 [10807940.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):928-33 [11237013.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1149-53 [11350878.001]
  • [Cites] Nat Rev Genet. 2001 Dec;2(12):930-42 [11733746.001]
  • [Cites] Pharmacogenomics J. 2001;1(4):254-61 [11908768.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jan;1(1):37-44 [12119608.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):417-29 [12167685.001]
  • [Cites] Drug Metab Dispos. 2002 Oct;30(10):1043-52 [12228178.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):529-37 [12571261.001]
  • [Cites] Int J Dermatol. 2003 May;42(5):335-41 [12755967.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):127-31 [12851835.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):209-13 [12938085.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1005-10 [14651971.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):425-31 [14762779.001]
  • [Cites] Mayo Clin Proc. 2004 Mar;79(3):376-84 [15008610.001]
  • [Cites] Drug Discov Today. 2004 Jul 1;9(13):574-81 [15203093.001]
  • [Cites] Ther Drug Monit. 2004 Apr;26(2):186-91 [15228163.001]
  • [Cites] Nat Rev Drug Discov. 2004 Sep;3(9):739-48 [15340384.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] J Pharmacol Exp Ther. 1982 Jul;222(1):174-81 [7086699.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1993;33:179-99 [8494339.001]
  • [Cites] Pharmacogenetics. 1992 Aug;2(4):148-59 [1306116.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2248-53 [7964939.001]
  • [Cites] DNA Cell Biol. 1995 Jan;14(1):1-6 [7832988.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949-53 [7862671.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1897-902 [7703493.001]
  • [Cites] Clin Pharmacol Ther. 1995 Nov;58(5):512-22 [7586945.001]
  • [Cites] DNA Cell Biol. 1996 Jan;15(1):17-30 [8561894.001]
  • [Cites] Am J Hum Genet. 1996 Apr;58(4):694-702 [8644731.001]
  • [Cites] Gut. 1996 Apr;38(4):578-81 [8707091.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6444-9 [9177237.001]
  • [Cites] J Inherit Metab Dis. 1997 Jul;20(3):335-8 [9266349.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):333-8 [9439663.001]
  • [Cites] Br J Cancer. 1998;77(1):79-86 [9459149.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):92-7 [9624244.001]
  • [Cites] Am J Hum Genet. 1998 Jul;63(1):11-6 [9634537.001]
  • (PMID = 17133087.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK052230; United States / NIDDK NIH HHS / DK / DK064399-05; United States / NCI NIH HHS / CA / R01 CA084197-09; United States / NIDDK NIH HHS / DK / R24 DK064399-05; United States / NCI NIH HHS / CA / CA084197-09; United States / NIDDK NIH HHS / DK / R01 DK052230-11; United States / NCI NIH HHS / CA / R01 CA084197; United States / NIDDK NIH HHS / DK / R24 DK064399; United States / NIDDK NIH HHS / DK / DK52230; United States / NIDDK NIH HHS / DK / DK052230-11; United States / NCI NIH HHS / CA / CA84197
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  • [Other-IDs] NLM/ NIHMS37179; NLM/ PMC2213557
  •  go-up   go-down


40. Speake D, Biyani D, Frizelle FA, Watson AJ: Flat adenomas. ANZ J Surg; 2007 Jan-Feb;77(1-2):4-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat adenomas.
  • This article was presented at the conjoint CSSA and RACS (colorectal section) spring meeting Queensland, Australia, September 2004.
  • The adenoma-carcinoma sequence describes a succession of events from polypoid adenoma to colorectal cancer.
  • However, this model only accounts for up to two-thirds of colorectal cancers.
  • There is growing evidence that flat adenomas are precursor lesions to a flat type of colorectal cancer and certain subtypes of these polyps are at greater risk of malignant transformation.
  • If confirmed, the implications for screening, endoscopic recognition and management will become of increasing importance if we are to decrease the incidence of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / physiopathology. Adenoma / physiopathology. Colonic Neoplasms / physiopathology. Colonic Polyps / physiopathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295810.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 72
  •  go-up   go-down


41. Alberts DS, Martínez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P, Phoenix and Tucson Gastroenterologist Networks: Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst; 2005 Jun 1;97(11):846-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
  • We conducted a phase III, double-blind placebo-controlled trial of UDCA to evaluate its ability to prevent colorectal adenoma recurrence.
  • METHODS: We randomly assigned 1285 individuals who had undergone removal of a colorectal adenoma within the past 6 months to daily treatment with UDCA (8-10 mg/kg of body weight; 661 participants) or with placebo (624 participants) for 3 years or until follow-up colonoscopy.
  • Recurrence rates (number of recurrent adenomas per unit time) were compared by use of a Huber-White variance estimator.
  • Proportions of participants with one or more recurrent adenomas were compared with a Pearson chi-square statistic; adjusted odds ratios (ORs) were obtained by logistic regression.
  • RESULTS: We observed a non-statistically significant 12% reduction in the adenoma recurrence rate associated with UDCA treatment, compared with placebo treatment.
  • However, UDCA treatment was associated with a statistically significant reduction (P = .03) in the recurrence of adenomas with high-grade dysplasia (adjusted OR = 0.61, 95% confidence interval = 0.39 to 0.96).
  • We observed no statistically significant differences between UDCA and placebo groups in recurrence with regard to adenoma size, villous histology, or location.
  • CONCLUSIONS: UDCA treatment was associated with a non-statistically significant reduction in total colorectal adenoma recurrence but with a statistically significant 39% reduction in recurrence of adenomas with high-grade dysplasia.
  • Because severely dysplastic lesions have a high risk of progression to invasive colorectal carcinoma, this finding indicates that future chemoprevention trials of UDCA in individuals with such lesions should be considered.
  • [MeSH-major] Adenoma / prevention & control. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / prevention & control. Neoplasm Recurrence, Local / prevention & control. Ursodeoxycholic Acid / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928305.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-23074; United States / NCI NIH HHS / CA / P01-CA-41108
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


42. Wang JY, Wang YH, Jao SW, Lu CY, Kuo CH, Hu HM, Hsieh JS, Chong IW, Cheng TL, Lin SR: Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. Oncol Rep; 2006 Dec;16(6):1245-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene.
  • Mutations of K-ras gene have been demonstrated in 40-50% of colorectal cancer and large adenoma (>1 cm).
  • This study was intended to clarify the correlation between the existence of K-ras oncogene and the pathological features of colorectal adenomas using our recently developed membrane arrays.
  • Moreover, the downstream genes regulated by K-ras oncogene were explored to serve as potential biomarkers in the early diagnosis and risk assessment of patients with colorectal adenoma.
  • Specimens were collected from 70 patients with colorectal adenoma.
  • Furthermore, activated K-ras oncogene was identified in 18 of 70 (25.7%) adenoma by membrane arrays.
  • The analysis of the correlation between the experimental data and pathological characteristics of adenoma showed that activated K-ras oncogenes were significantly associated with the size, number and histology of adenomas (all P<0.001).
  • Finally, we found the downstream genes activated by K-ras oncogene, including B-cell CLL/lymphoma 2 (BCL2), Homo sapiens H2A histone family, member Z (H2AFZ), Homo sapiens RAP1B, member of RAS oncogene family (RAP1B), Homo sapiens T-box 19 (TBX19), Homo sapiens E2F transcription factor 4, p107/p130-binding (E2F4) and matrix metallopeptidase 1 (MMP1), of which were overexpressed in most of all examined adenomas.
  • Therefore, we propose that activated K-ras oncogene in colorectal adenomas may play an important role in the subsequent colorectal carcinogenesis through a group of K-ras-related molecular targets.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Genes, ras

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089045.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


43. Vinikoor LC, Schroeder JC, Millikan RC, Satia JA, Martin CF, Ibrahim J, Galanko JA, Sandler RS: Consumption of trans-fatty acid and its association with colorectal adenomas. Am J Epidemiol; 2008 Aug 1;168(3):289-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consumption of trans-fatty acid and its association with colorectal adenomas.
  • To investigate the association between colorectal adenomas and trans-fatty acid consumption, the authors utilized data from a cross-sectional study of 622 individuals who underwent complete colonoscopy between 2001 and 2002 at the University of North Carolina Hospitals.
  • Participants were interviewed about demographic, lifestyle, and dietary factors thought to be related to colorectal cancer. trans-Fatty acid consumption, energy adjusted by the residual method, was categorized into quartiles based on its distribution in controls.
  • Compared with participants in the lowest quartile of consumption, those in the highest quartile had an increased prevalence of colorectal adenomas, with an adjusted prevalence odds ratio of 1.86 (95% confidence interval: 1.04, 3.33).
  • The authors further investigated the relation between trans-fatty acid consumption and colorectal neoplasia by examining the adenoma characteristics, with the adjusted prevalence odds ratios showing little or no difference by adenoma location, size, or number.
  • These results suggest that consumption of high amounts of trans-fatty acid may increase the risk of colorectal neoplasia, and they provide additional support to recommendations to limit trans-fatty acid consumption.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2002 Dec;123(6):1770-7 [12454832.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):42-7 [17631129.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] Epidemiology. 2000 Jul;11(4):469-73 [10874557.001]
  • [Cites] Am J Epidemiol. 2000 Aug 1;152(3):279-86 [10933275.001]
  • [Cites] Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504 [10993420.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1271-9 [11142411.001]
  • [Cites] Ann Epidemiol. 2001 Feb;11(2):145-53 [11164131.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 5;93(17):1282-3 [11535695.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] Nutr Cancer. 2001;39(2):170-5 [11759276.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] J Am Diet Assoc. 2002 Feb;102(2):212-25 [11846115.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1524-9 [12094877.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] Int J Epidemiol. 2003 Apr;32(2):200-9 [12714537.001]
  • [Cites] Br J Nutr. 2003 May;89(5):631-9 [12720583.001]
  • [Cites] Fed Regist. 2003 Jul 11;68(133):41433-1506 [12856667.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):328-36 [12891533.001]
  • [Cites] Am J Clin Nutr. 2004 Apr;79(4):606-12 [15051604.001]
  • [Cites] Can J Surg. 1978 May;21(3):206-8 [647507.001]
  • [Cites] Am J Epidemiol. 1985 Nov;122(5):794-804 [3876763.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 15;84(2):91-8 [1310511.001]
  • [Cites] Ann Intern Med. 1993 Jan 15;118(2):91-5 [8416323.001]
  • [Cites] J Nutr. 1993 Nov;123(11):1808-17 [8229295.001]
  • [Cites] Cancer Causes Control. 1995 Jan;6(1):45-56 [7718735.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2293-8 [7757978.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1760-6 [7473832.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):423-9 [9247459.001]
  • [Cites] Am J Clin Nutr. 1997 Dec;66(6 Suppl):1564S-1571S [9394716.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):69-75 [9950242.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):519-24 [10385142.001]
  • [Cites] Am J Epidemiol. 2004 Nov 15;160(10):1011-22 [15522858.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2059-60 [16103463.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2789-95 [16393237.001]
  • [Cites] Atheroscler Suppl. 2006 May;7(2):37-9 [16713388.001]
  • [Cites] Nutr Rev. 2006 Aug;64(8):364-72 [16958313.001]
  • [Cites] Nutr Clin Pract. 2006 Oct;21(5):505-12 [16998148.001]
  • [Cites] Am J Clin Nutr. 2006 Nov;84(5):981-8 [17093147.001]
  • [Cites] J Nutr. 2006 Dec;136(12):3054-61 [17116719.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] N Engl J Med. 2007 May 17;356(20):2017-21 [17507699.001]
  • [Cites] Am J Epidemiol. 2007 Jul 15;166(2):181-95 [17493949.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • (PMID = 18587137.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA044684; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NCI NIH HHS / CA / R01CA44684; United States / NIDDK NIH HHS / DK / P30DK34987; United States / NIDDK NIH HHS / DK / T32 DK007634; United States / NIDDK NIH HHS / DK / T32DK07634
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Trans Fatty Acids
  • [Other-IDs] NLM/ NIHMS64890; NLM/ PMC2533637
  •  go-up   go-down


44. Otani T, Iwasaki M, Ikeda S, Kozu T, Saito H, Mutoh M, Wakabayashi K, Tsugane S: Serum triglycerides and colorectal adenoma in a case-control study among cancer screening examinees (Japan). Cancer Causes Control; 2006 Dec;17(10):1245-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum triglycerides and colorectal adenoma in a case-control study among cancer screening examinees (Japan).
  • OBJECTIVE: Most epidemiologic studies have shown serum triglycerides to be associated with colorectal adenoma.
  • We cross-sectionally investigated the association of serum triglycerides with the risk of adenoma by smoking status.
  • METHODS: We identified 782 newly diagnosed adenoma cases from the examinees of a colorectal cancer screening program.
  • We determined 738 controls without present illness or past history of adenoma from among the examinees.
  • We calculated odds ratios (OR) and 95% confidence intervals (CI) of colorectal adenoma for serum triglycerides.
  • RESULTS: High serum triglycerides were associated with colorectal adenoma (OR 1.5; 95% CI 1.1-2.0 for the highest versus the lowest quartile, P (trend, )0.030).
  • A stronger association was observed between three or more adenoma cases and study controls (OR 2.3; 95% CI 1.3-4.2, P (trend,) < 0.0010).
  • CONCLUSIONS: Our results suggested that a higher serum triglyceride level may be related to a larger number of adenomas.
  • Adenoma development involving an elevated serum triglyceride level may be modified by smoking.
  • [MeSH-major] Adenoma / blood. Adenoma / diagnosis. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Mass Screening. Triglycerides / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111255.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Triglycerides
  •  go-up   go-down


45. Caswell S, Anderson AS, Steele RJ: Diet and physical activity in patients with colorectal adenomas: directions for intervention programmes. J Hum Nutr Diet; 2008 Oct;21(5):494-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diet and physical activity in patients with colorectal adenomas: directions for intervention programmes.
  • The aim of the current exploratory research was to identify diet and activity habits in adults diagnosed with colorectal adenomas on screening colonoscopy in order to inform the development of an intervention study in this patient group.
  • [MeSH-major] Adenoma / prevention & control. Colorectal Neoplasms / prevention & control. Diet. Exercise

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Seniors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18631284.001).
  • [ISSN] 1365-277X
  • [Journal-full-title] Journal of human nutrition and dietetics : the official journal of the British Dietetic Association
  • [ISO-abbreviation] J Hum Nutr Diet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Carbohydrates; 0 / Dietary Fats; 0 / Dietary Proteins
  •  go-up   go-down


46. Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T, Matsumoto A, Osawa G, Onda M, Ogawa K: Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas. Anticancer Res; 2007 Jan-Feb;27(1A):127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas.
  • To investigate the involvement of XBP-1 in colorectal tumorigenecity, the expression of XBP-1 was examined in four colon cancer cell lines, six colorectal polyps and five colorectal carcinomas.
  • MATERIALS AND METHODS: The study population consisted of eleven patients who had undergone resection for colorectal cancer or adenoma from 2000 to 2002.
  • RESULTS: The XBP-1 gene was overexpressed in four cases out of five primary colorectal carcinomas and in four cases out of six colorectal adenomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352224.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / regulatory factor X transcription factors
  •  go-up   go-down


47. Greenhough A, Wallam CA, Hicks DJ, Moorghen M, Williams AC, Paraskeva C: The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene; 2010 Jun 10;29(23):3398-410
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells.
  • Overexpression of cyclooxygenase-2 (COX-2) and elevated levels of its enzymatic product prostaglandin E2 (PGE(2)) occur in the majority of colorectal cancers and have important roles in colorectal tumorigenesis.
  • Here, we have shown that PGE(2) suppresses apoptosis via repression of the proapoptotic BH3-only protein Bim in human colorectal adenoma cells.
  • Reduction of Bim expression using RNA interference reduced spontaneous apoptosis in adenoma cells and abrogated PGE(2)-dependent apoptosis suppression.
  • Treatment of COX-2-expressing colorectal carcinoma cells with COX-2-selective NSAIDs-induced Bim expression, suggesting that Bim repression via PGE(2) signalling may be opposed by COX-2 inhibition.
  • Examination of Bim expression in two established in vitro models of the adenoma-carcinoma sequence revealed that downregulation of Bim expression was associated with tumour progression towards an anchorage-independent phenotype.
  • Finally, immunohistochemical analyses revealed that Bim expression is markedly reduced in approximately 40% of human colorectal carcinomas in vivo.
  • These observations highlight the COX-2/PGE(2) pathway as an important negative regulator of Bim expression in colorectal tumours and suggest that Bim repression may be an important step during colorectal cancer tumorigenesis.
  • [MeSH-major] Adenoma / etiology. Apoptosis Regulatory Proteins / physiology. Colorectal Neoplasms / etiology. Cyclooxygenase 2 / physiology. Dinoprostone / physiology. Membrane Proteins / physiology. Proto-Oncogene Proteins / physiology. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):733-40 [12844146.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6785-93 [14555991.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):8837-47 [14681225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6164-9 [15079075.001]
  • [Cites] J Biol Chem. 2004 Jul 9;279(28):29797-804 [15123663.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):285-95 [15380519.001]
  • [Cites] Cancer Res. 1989 Mar 1;49(5):1282-6 [2917357.001]
  • [Cites] Cancer Res. 1990 Aug 1;50(15):4724-30 [2369746.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3367-70 [7936663.001]
  • [Cites] J Cell Sci. 1994 Dec;107 ( Pt 12):3569-77 [7706406.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1822-9 [15753380.001]
  • [Cites] Oncogene. 2008 Dec 4;27(57):7150-61 [18806830.001]
  • [Cites] Cell. 2008 Dec 12;135(6):1074-84 [19062087.001]
  • [Cites] Mol Cell. 2009 Jan 16;33(1):109-16 [19150432.001]
  • [Cites] Cell Death Differ. 2009 Mar;16(3):368-77 [18846109.001]
  • [Cites] Carcinogenesis. 2009 Mar;30(3):377-86 [19136477.001]
  • [Cites] Cell. 2009 Mar 20;136(6):1136-47 [19303855.001]
  • [Cites] J Cell Biol. 2009 Apr 20;185(2):279-90 [19380879.001]
  • [Cites] Trends Mol Med. 2009 May;15(5):225-33 [19362056.001]
  • [Cites] Oncogene. 2010 Feb 11;29(6):781-8 [19946329.001]
  • [Cites] Science. 1999 Nov 26;286(5445):1735-8 [10576740.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):227-38 [15766661.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2317-29 [15688014.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1811-6 [7728743.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2273-6 [8625297.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2422-7 [8625322.001]
  • [Cites] Biochem Pharmacol. 1996 Jul 26;52(2):237-45 [8694848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):681-6 [9435252.001]
  • [Cites] Nat Med. 1998 Apr;4(4):392-3 [9546780.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8148-51 [15548677.001]
  • [Cites] Mol Cell. 2005 Feb 4;17(3):393-403 [15694340.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1348-58 [15608680.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1008-14 [15947788.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3106-13 [16540660.001]
  • [Cites] Cancer Cell. 2006 May;9(5):351-65 [16697956.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6683-91 [16818642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12 [16997913.001]
  • [Cites] Cell Death Differ. 2007 Jan;14(1):137-45 [16645643.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):210-7 [17220880.001]
  • [Cites] Science. 2007 Feb 9;315(5813):856-9 [17289999.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3787-92 [17360431.001]
  • [Cites] Oncogene. 2007 May 10;26(21):3006-19 [17130837.001]
  • [Cites] EMBO J. 2007 Jun 20;26(12):2856-67 [17525735.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1337-49 [17604722.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2172-80 [17583570.001]
  • [Cites] Oncogene. 2007 Oct 25;26(49):7038-48 [17486061.001]
  • [Cites] PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680 [17973572.001]
  • [Cites] PLoS Med. 2007 Oct;4(10):1681-89; discussion 1690 [17973573.001]
  • [Cites] PLoS Med. 2007 Oct 9;4(10):e294 [17927446.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] Carcinogenesis. 2008 Apr;29(4):849-57 [18204076.001]
  • [Cites] Oncogene. 2008 Apr 17;27(18):2648-55 [18059344.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5810-8 [18794091.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Oct;21(5):534-44 [18715233.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1076-81 [18948948.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3651-9 [18949058.001]
  • [Cites] Carcinogenesis. 2000 Jan;21(1):69-77 [10607736.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):449-61 [10934149.001]
  • [Cites] Curr Biol. 2000 Oct 5;10(19):1201-4 [11050388.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Mol Cell. 2001 Sep;8(3):705-11 [11583631.001]
  • [Cites] FASEB J. 2001 Dec;15(14):2742-4 [11606477.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):183-92 [12242151.001]
  • [Cites] J Pathol. 2002 Dec;198(4):428-34 [12434411.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1281-93 [12618753.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):18811-6 [12646560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8921-6 [12837940.001]
  • (PMID = 20348947.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A5301; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BAD protein, human; 0 / BCL2L11 protein, human; 0 / Bcl-2-Like Protein 11; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / bcl-Associated Death Protein; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2883743; NLM/ UKMS28872
  •  go-up   go-down


48. Hsu CH, Taylor JM, Long Q, Alberts DS: Analysis of colorectal adenoma recurrence data subject to informative censoring. Cancer Epidemiol Biomarkers Prev; 2009 Mar;18(3):712-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of colorectal adenoma recurrence data subject to informative censoring.
  • The treatment effect of a colorectal polyp prevention trial is often evaluated from the colorectal adenoma recurrence status at the end of the trial.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Stat Med. 1988 Nov;7(11):1139-45 [3201039.001]
  • [Cites] Biometrics. 1992 Sep;48(3):951-9 [1420849.001]
  • [Cites] Stat Med. 1992 Sep 15;11(12):1569-78 [1439361.001]
  • [Cites] Biometrics. 1996 Mar;52(1):137-51 [8934589.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):846-53 [15928305.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Stat Med. 2006 Oct 30;25(20):3503-17 [16345047.001]
  • [Cites] Stat Med. 2007 Mar 30;26(7):1567-78 [16850435.001]
  • (PMID = 19240239.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / P30 CA023074-30; United States / NCI NIH HHS / CA / CA041108-22; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / CA041108-21; United States / NCI NIH HHS / CA / P30 CA023074-28; None / None / / P30 CA023074-30; United States / NCI NIH HHS / CA / P01 CA041108; United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / P01 CA041108-21; United States / NCI NIH HHS / CA / P01 CA041108-22; United States / NCI NIH HHS / CA / CA41108
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  • [Other-IDs] NLM/ NIHMS104698; NLM/ PMC2668929
  •  go-up   go-down


49. Bertagnolli MM: Cox-2 and cancer chemoprevention: picking up the pieces. Recent Results Cancer Res; 2007;174:73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recent reports of cardiovascular adverse events in patients treated with selective Cox-2 inhibitors for colorectal adenoma prevention remind us that all therapies carry risks as well as benefits.
  • This article will discuss the biologic rationale for using selective Cox-2 inhibitors in cancer chemoprevention, and outline new avenues of research necessary to allow their successful use in patients at risk for colorectal cancer.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302187.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 41
  •  go-up   go-down


50. Kang HW, Kim D, Kim HJ, Kim CH, Kim YS, Park MJ, Kim JS, Cho SH, Sung MW, Jung HC, Lee HS, Song IS: Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol; 2010 Jan;105(1):178-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study.
  • OBJECTIVES: Colorectal adenoma is known to be associated with obesity, but the association between colorectal adenoma and visceral adipose tissue (VAT) area measured by abdominal computed tomography (CT) has not been documented clearly.
  • In addition, the relationship between insulin resistance and colorectal adenomas, which underlies the mechanism that links obesity and colorectal adenoma, has not been studied extensively.
  • The aim of this study was to examine VAT area and insulin resistance as risk factors of colorectal adenoma.
  • VAT, subcutaneous adipose tissue (SAT), and homeostatic metabolic assessment (HOMA) index were evaluated as potential risk factors of colorectal adenoma in 2,244 age- and sex-matched subjects.
  • RESULTS: According to univariate analysis, the prevalences of smoking, hypertension, metabolic syndrome, and family history of colorectal cancer were higher in the adenoma group than in the normal control group.
  • According to the multivariate analysis adjusted for multiple confounders, VAT area was independently associated with the risk of colorectal adenoma (odds ratio (OR)=3.09, 95% confidence interval (CI): 2.19-4.36, highest quintile vs. lowest quintile).
  • Mean HOMA index was higher in the adenoma group than in the control group (OR=1.99, 95% CI: 1.35-2.92, highest vs. lowest quintile).
  • CONCLUSIONS: Visceral obesity was found to be an independent risk factor of colorectal adenoma, and insulin resistance was associated with the presence of colorectal adenoma.
  • [MeSH-major] Adenoma / etiology. Colorectal Neoplasms / etiology. Insulin Resistance. Intra-Abdominal Fat / pathology. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2010 Jul;105(7):1677 [20606672.001]
  • (PMID = 19755965.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


51. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med; 2005 Mar 17;352(11):1092-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
  • We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas.
  • METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo.
  • CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
  • [MeSH-major] Adenomatous Polyps / prevention & control. Cardiovascular Diseases / chemically induced. Colorectal Neoplasms / prevention & control. Cyclooxygenase Inhibitors / adverse effects. Lactones / adverse effects. Sulfones / adverse effects. Thrombosis / chemically induced


52. Bresalier RS: Chemoprevention of colorectal cancer: why all the confusion? Curr Opin Gastroenterol; 2008 Jan;24(1):48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of colorectal cancer: why all the confusion?
  • PURPOSE OF REVIEW: Chemoprevention provides an opportunity to complement screening for the prevention of colorectal neoplasia.
  • RECENT FINDINGS: A recent prospective randomized trial demonstrates that folic acid supplementation in patients with a previous history of colorectal adenomas does not reduce future colorectal adenoma risk, and may possibly increase the risk of colorectal neoplasia.
  • [MeSH-major] Colorectal Neoplasms / prevention & control. Diet. Folic Acid / pharmacology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043232.001).
  • [ISSN] 1531-7056
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 935E97BOY8 / Folic Acid; SY7Q814VUP / Calcium
  • [Number-of-references] 13
  •  go-up   go-down


53. Taylor JC, Kendall CA, Stone N, Cook TA: Optical adjuncts for enhanced colonoscopic diagnosis. Br J Surg; 2007 Jan;94(1):6-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical adjuncts for enhanced colonoscopic diagnosis.
  • BACKGROUND: Optical techniques using previously unexploited properties of light interaction with tissue may be valuable in the detection, diagnosis and staging of colorectal neoplasia.
  • METHODS: A Medline search (1990 to present) was conducted on optical diagnostics in the detection of colorectal neoplasia.
  • RESULTS AND CONCLUSION: Chromoendoscopy is the only optical adjunct to colonoscopy that has been tested in large randomized clinical trials.
  • It improves the detection of small and flat colorectal adenomas, and of neoplasia in chronic ulcerative colitis and hereditary non-polyposis colorectal cancer.
  • Optical techniques may, however, permit immediate clinical diagnosis, removing the need for histological analysis.
  • They may also improve the diagnosis of early colonic neoplasia.
  • [MeSH-major] Colonoscopy / methods. Colorectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 17205497.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / CSA/03/07/017
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 87
  •  go-up   go-down


54. Wang J, Wang X, Gong W, Mi B, Liu S, Jiang B: Increased expression of beta-catenin, phosphorylated glycogen synthase kinase 3beta, cyclin D1, and c-myc in laterally spreading colorectal tumors. J Histochem Cytochem; 2009 Apr;57(4):363-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of beta-catenin, phosphorylated glycogen synthase kinase 3beta, cyclin D1, and c-myc in laterally spreading colorectal tumors.
  • Laterally spreading tumors (LSTs) are considered a special subtype of superficial colorectal tumor.
  • This study was performed to characterize the clinicopathological features and examine activation of the Wnt/beta-catenin pathway in LSTs and protruded-type colorectal adenomas (PAs).
  • [MeSH-major] Colorectal Neoplasms / metabolism. Cyclin D1 / biosynthesis. Glycogen Synthase Kinase 3 / biosynthesis. Proto-Oncogene Proteins c-myc / biosynthesis. beta Catenin / biosynthesis
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / biosynthesis. Humans. Immunohistochemistry. Phosphorylation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3323-7 [10910031.001]
  • [Cites] Histopathology. 2008 Apr;52(5):569-77 [18370954.001]
  • [Cites] Gastrointest Endosc. 2001 Jul;54(1):62-6 [11427843.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jul;16(7):770-6 [11446885.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1124-9 [11953860.001]
  • [Cites] Virchows Arch. 2002 May;440(5):453-60 [12021919.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8683-8 [12072559.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Dec;17(12):1344-5 [12423287.001]
  • [Cites] Dig Liver Dis. 2003 Mar;35(3):165-71 [12779070.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):5-6 [14749120.001]
  • [Cites] Endoscopy. 2004 Apr;36(4):306-12 [15057679.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):455-61 [8261988.001]
  • [Cites] Oncology. 1996 Mar-Apr;53(2):89-93 [8604246.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1438-9, 1441 [9750112.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1365-73 [16043125.001]
  • [Cites] Gut. 2005 Oct;54(10):1504-5 [16162961.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Oct;20(10):1584-90 [16174078.001]
  • [Cites] J Pathol. 2006 Jan;208(1):91-9 [16278819.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):178-83 [16377346.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):311-7 [16404419.001]
  • [Cites] J Gastroenterol. 2006 Apr;41(4):325-31 [16741611.001]
  • [Cites] Gastroenterology. 2006 Aug;131(2):379-89 [16890591.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):203-12 [16298038.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):3065-72 [17011185.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):139-47 [17143260.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Jan;22(1):30-6 [17201877.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):150-8 [17306971.001]
  • [Cites] Mol Carcinog. 2008 Jan;47(1):1-8 [17620311.001]
  • [Cites] Int J Cancer. 2001 May 20;95(3):194-7 [11307154.001]
  • (PMID = 19064714.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / beta Catenin; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / glycogen synthase kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC2664982
  •  go-up   go-down


55. Arslan N, Dehdashti F, Siegel BA: FDG uptake in colonic villous adenomas. Ann Nucl Med; 2005 Jun;19(4):331-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG uptake in colonic villous adenomas.
  • Colonic adenomas constitute 70-80% of all colorectal polyps, and their clinical significance relates primarily to their relationship with colorectal cancer.
  • The malignant potential of the polyps detected by FDG-PET is unknown, as not all the colonic lesions identified by FDG-PET represent colorectal malignancies.
  • The purpose of this study was to investigate the rate of FDG-PET positivity within colonic villous adenomas.
  • A pathology database search was performed to identify all patients diagnosed with colonic villous adenoma between June 1, 1996 and December 1, 2000.
  • Patients with a pathologic diagnosis of colonic villous adenoma and who also had a FDG-PET study up to 1 month before colonoscopy were included in this study.
  • Of more than 4,000 patients, six patients were diagnosed with colonic adenoma on subsequent colonoscopy following FDG-PET study.
  • Based on the pathological findings, these 6 patients had a total of 2 villous and 9 tubulovillous adenomas.
  • Five of the 6 patients showed foci of increased FDG uptake in the region of the colon that corresponded to the villous adenoma(s) detected on colonoscopy, which accounted for a true-positive rate of 83.3% (5/6 subjects).
  • Focal lesions in the colon seen on FDG-PET examinations need to be investigated further, even though some of these will prove to be villous adenomas rather than colorectal carcinomas.
  • [MeSH-major] Adenoma, Villous / radionuclide imaging. Colorectal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097645.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. Li ZX, Zeng SD, Liu YD, Liao YJ, Hua WF, Lin F, Xie D: [Clinicopathological significance of expression and amplification of P21-activated kinase 1 gene in colorectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Mar;12(2):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological significance of expression and amplification of P21-activated kinase 1 gene in colorectal carcinoma].
  • OBJECTIVE: To investigate the clinicopathological value of the expression and amplification of P21-activated kinase 1 gene (PAK1) in colorectal carcinoma(CRC).
  • METHODS: Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling(TUNEL) methods were used to examine the protein expression, amplification of PAK1 and cell apoptosis in 80 cases of CRC and 30 cases of colorectal adenoma by tissue microarray.
  • RESULTS: IHC showed an overexpression of PAK1 protein in 26% of colorectal adenomas and 62% of CRCs.
  • CONCLUSIONS: Overexpression of PAK1 protein may play an important role in development and progression of colorectal neoplasms and it is closely associated with the malignant histological and invasive phenotype of CRCs.
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. p21-Activated Kinases / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296259.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.1 / PAK1 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


57. Boutron-Ruault MC, Marteau P, Lavergne-Slove A, Myara A, Gerhardt MF, Franchisseur C, Bornet F, Eripolyp Study Group: Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas. Nutr Cancer; 2005;53(2):160-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas.
  • Intervention studies of colorectal adenoma recurrence have demonstrated the need for surrogate markers of the cancer risk.
  • We investigated differences in biological markers between adenoma and adenoma-free subjects, before and after 3 mo of daily intake of 10 g sc-FOS, within a multicenter study.
  • After a full colonoscopy, 3 groups were studied at baseline and after 3 mo: 26 subjects with small colorectal adenoma(s), 18 with large adenoma(s), and 30 with no adenoma.
  • At baseline, the mean fecal butyrate concentration was significantly lower in the adenoma groups than in the adenoma-free group (12.01 +/- 5.08 vs. 17.28 +/- 7.34 mmol/g dry weight) but was significantly increased in that group after 3-mo ingestion of sc-FOS (15.7 +/- 8.0 mmol/g; P = 0.02).
  • In subjects without adenoma, sc-FOS ingestion was associated with a decrease in fecal lithocholic acid (P = 0.02) and an increase in cholic acid (P = 0.02), chenodeoxycholic acid (P = 0.04), total primary bile acids (P = 0.03), and ursodeoxycholic acid (P = 0.05).
  • In subjects with and without adenoma, sc-FOS affects some aspects of the colonic environment, which may be involved in prevention of colorectal neoplasia.
  • [MeSH-major] Adenoma / drug therapy. Colorectal Neoplasms / drug therapy. Feces / chemistry. Oligosaccharides / pharmacology

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573377.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers; 0 / Butyrates; 0 / Oligosaccharides; 0 / fructooligosaccharide; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


58. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, Kedra B, Konopko M, Szmitkowski M: The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin Chim Acta; 2006 Sep;371(1-2):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients.
  • Cancer cells, including colorectal cancer, can produce this cytokine.
  • The aim of this study was to compare the diagnostic value of measurement of G-CSF and classic tumor markers--carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in the sera of colorectal cancer with adenoma patients and to determine its usefulness in the diagnosis of colorectal cancer and polyps.
  • PATIENTS AND METHODS: The serum levels of G-CSF and tumor markers were assayed in 76 colorectal cancer, 35 colorectal adenoma patients and in 65 healthy subjects.
  • RESULTS: Median values of G-CSF and tumor markers were significantly higher in colorectal cancer patients than those in healthy subjects.
  • There were significant differences in the serum levels of G-CSF between adenoma patients and healthy subjects.
  • The concentrations of tumor markers in colorectal cancer patients were higher than those in polyps.
  • Combined use of G-CSF with CEA improved their diagnostic sensitivity in colorectal cancer.
  • CONCLUSIONS: Measurement of G-CSF might be useful in the diagnosis of colorectal cancer patients, but not in the differentiation between colorectal cancer and polyps.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Granulocyte Colony-Stimulating Factor / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603145.001).
  • [ISSN] 0009-8981
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


59. Baron JA: Statins and the colorectum: hope for chemoprevention? Cancer Prev Res (Phila); 2010 May;3(5):573-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This perspective on Bertagnolli et al. (beginning on p. 588 in this issue of the journal) and Lipkin et al. (beginning on p. 597) considers the likelihood that statins have chemopreventive efficacy in the large bowel.
  • An observational analysis within a clinical trial of celecoxib found no benefit of statin use on the risk of colorectal adenomas (and some suggestions of an adverse effect).
  • On the other hand, variation in the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene modified the association of statins with risk of colorectal cancer.
  • [MeSH-major] Chemoprevention / methods. Colorectal Neoplasms / prevention & control. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Prev Res (Phila). 2010 May;3(5):588-96 [20403998.001]
  • [CommentOn] Cancer Prev Res (Phila). 2010 May;3(5):597-603 [20403997.001]
  • (PMID = 20403999.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Antineoplastic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • [Number-of-references] 27
  •  go-up   go-down


60. Kloor M, Michel S, Buckowitz B, Rüschoff J, Büttner R, Holinski-Feder E, Dippold W, Wagner R, Tariverdian M, Benner A, Schwitalle Y, Kuchenbuch B, von Knebel Doeberitz M: Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer; 2007 Jul 15;121(2):454-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta2-microglobulin mutations in microsatellite unstable colorectal tumors.
  • MSI-H cancers may develop either sporadically or in the context of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome that is caused by germline mutations of MMR genes.
  • In colorectal cancer (CRC), MSI-H is characterized by a dense lymphocytic infiltration, reflecting a high immunogenicity of these cancers.
  • To examine the implications of beta2m mutations during MSI-H colorectal tumor development, we analyzed the prevalence of beta2m mutations in MSI-H colorectal adenomas (n=38) and carcinomas (n=104) of different stages.
  • Mutations were observed in 6/38 (15.8%) MSI-H adenomas and 29/104 (27.9%) MSI-H CRCs.
  • The high frequency of beta2m mutations in HNPCC-associated MSI-H CRCs is in line with the hypothesis that immunoselection may be particularly pronounced in HNPCC patients with inherited predisposition to develop MSI-H cancers. beta2m mutations were positively related to stage in tumors without distant metastases (UICC I-III), suggesting that loss of beta2m expression may promote local progression of colorectal MSI-H tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Microsatellite Repeats / genetics. Mutation. beta 2-Microglobulin / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17373663.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / beta 2-Microglobulin; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


61. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J: PTGS2 (COX-2) -765G &gt; C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):616-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs.
  • For colorectal adenoma, odds ratios (OR) compared with PTGS2 -765GG as reference were GC 1.00 [95% confidence interval (95% CI), 0.74-1.35] and CC 0.53 (95% CI, 0.22-1.28).
  • Among nonusers of aspirin or other NSAIDs, the CC genotype conferred a significant decrease in risk of adenoma (OR, 0.26; 95% CI, 0.07-0.89).
  • Use of aspirin or other NSAIDs reduced risk of adenoma only among those with the -765GG (wild type) and possibly -765CG genotypes (OR, 0.66; 95% CI, 0.48-0.92 and OR, 0.64; 95% CI, 0.40-1.02, respectively).
  • These data suggest that COX-2 expression or activity may be beneficially suppressed, and risk of colorectal polyps reduced, by aspirin or other NSAIDs in PTGS2 -765GG (wild type) individuals and by the -765 CC variant genotype in nonusers of NSAIDs.
  • [MeSH-major] Adenoma / genetics. Adenoma / prevention & control. Colorectal Neoplasms / genetics. Colorectal Neoplasms / prevention & control. Peroxidases / genetics. Polymorphism, Genetic. Prostaglandin-Endoperoxide Synthases / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858269 for PMID:15767339 [PharmGKB] .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):3020
  • (PMID = 15767339.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA59045; United States / NCI NIH HHS / CA / R01CA89445
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Membrane Proteins; EC 1.11.1.- / Peroxidases; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


62. Moreira LR, Schenka AA, Filho PL, Lima CS, Trevisan MA, Vassallo J: Comparison of blood neoangiogenesis and lymphatic vascularization in colorectal adenomas from patients with and without concomitant colorectal cancer. Braz J Med Biol Res; 2009 Jul;42(7):593-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of blood neoangiogenesis and lymphatic vascularization in colorectal adenomas from patients with and without concomitant colorectal cancer.
  • Most colorectal carcinomas develop from adenomas (adenoma-carcinoma sequence) in a process due to accumulation of molecular genetic alterations.
  • Adenomas from patients with carcinoma showed significantly higher values of total vascular area determined by immunostaining for CD105 (cutoff value = 4386 microm(2); P = 0.019) and of lymphatic microvessel density determined by immunostaining with D2-40 (cutoff value = 11.5; P = 0.041) when compared with those from patients without cancer.
  • The present data indicate a significant increase in blood microvascular area and in lymphatic microvascular counts in adenomas removed from patients with cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19466284.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Biomarkers; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / monoclonal antibody D2-40
  •  go-up   go-down


63. Rowan A, Halford S, Gaasenbeek M, Kemp Z, Sieber O, Volikos E, Douglas E, Fiegler H, Carter N, Talbot I, Silver A, Tomlinson I: Refining molecular analysis in the pathways of colorectal carcinogenesis. Clin Gastroenterol Hepatol; 2005 Nov;3(11):1115-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refining molecular analysis in the pathways of colorectal carcinogenesis.
  • BACKGROUND & AIMS: In the stepwise model, specific genetic and epigenetic changes accumulate as colorectal adenomas progress to carcinomas (CRCs).
  • [MeSH-major] Carcinoma / genetics. Colorectal Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271343.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Martínez ME, Jacobs ET, Ashbeck EL, Sinha R, Lance P, Alberts DS, Thompson PA: Meat intake, preparation methods, mutagens and colorectal adenoma recurrence. Carcinogenesis; 2007 Sep;28(9):2019-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat intake, preparation methods, mutagens and colorectal adenoma recurrence.
  • Red meat intake has been shown to be associated with higher risk of colorectal cancer.
  • We prospectively assessed the relation between type of meat, meat preparation method, doneness, a metric of HCAs and other mutagens and colorectal adenoma recurrence among 869 participants in a chemoprevention trial of ursodeoxycholic acid.
  • Most meat variables assessed were positively but weakly associated with recurrence of any adenoma.
  • In contrast, recurrence of advanced or multiple adenomas was more strongly associated with a number of the meat exposure variables evaluated.
  • Significant positive associations were shown for recurrence of multiple adenomas and the following variables: processed meat (OR = 1.83; 95% CI = 1.10-3.04), pan-fried red meat (OR = 1.63; 95% CI = 1.01-2.61), well/very well done red meat (OR = 1.68; 95% CI = 1.03-2.74), 2-amino-3,4,8-trimethylimidazo[4,5,-f]quinoxaline (OR = 1.74; 95% CI = 1.07-2.82) and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (OR = 1.68; 95% CI = 1.03-2.75).
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Cooking / methods. Meat / analysis. Mutagens / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690112.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-23074; United States / NCI NIH HHS / CA / CA-41108; United States / NCI NIH HHS / CA / CA106269; United States / NCI NIH HHS / CA / CA95060
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Mutagens; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


65. Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR: Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis. Clin Gastroenterol Hepatol; 2009 Dec;7(12):1272-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and meta-analysis.
  • BACKGROUND & AIMS: There is an extensive yet inconsistent body of literature reporting on the prevalence of adenomatous polyps (adenomas) and colorectal cancer among average risk individuals.
  • The objectives of our study were to determine the pooled prevalence of adenomas and colorectal cancer, as well as nonadvanced and advanced adenomas, among average risk North Americans.
  • Two reviewers independently selected cross-sectional studies reporting adenoma and colorectal cancer prevalence rates in average risk individuals and assessed studies for inclusion and quality, and extracted the data for analysis.
  • Pooled adenoma and colorectal cancer prevalence rates were estimated using fixed and random effects models.
  • RESULTS: Based on 18 included studies, the pooled prevalence of adenomas, colorectal cancer, nonadvanced adenomas, and advanced adenomas was 30.2%, 0.3%, 17.7%, and 5.7%, respectively.
  • Heterogeneity was observed in the pooled prevalence rates for overall adenomas, advanced adenomas, and colorectal cancer and was explained by the mean age (> or = 65 years vs < 65 years) with older cohorts reporting higher prevalence rates.
  • CONCLUSIONS: The high prevalence of advanced adenomas and colorectal cancer, especially among older screen-eligible individuals, provides impetus for expanding colorectal cancer screening programs.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523536.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


66. Cao J, Chen XP, Li WL, Xia J, Du H, Tang WB, Wang H, Chen XW, Xiao HQ, Li YY: Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition. World J Gastroenterol; 2007 Feb 21;13(7):1018-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition.
  • AIM: To detect the expression of fragile histidine triad (FHIT) in normal colorectal tissue, colorectal adenoma and colorectal cancer (CRC) tissue, and to analyze its relationship with the clinicopathological features of CRC, and apoptosis-associated proteins (Bcl-2, Bax, survivin) and apoptosis in colorectal cancer.
  • Tissue microarray (TMA) was established to detect the expression of FHIT, Bcl-2, Bax and survivin genes in 80 CRC tissue specimens, 16 colorectal adenoma tissue specimens and 16 hemorrhoid (PPH) tissue specimens during the same period of time as the control.
  • RESULTS: Ten out of 26 (38.5%) CRC tissue specimens expressed aberrant FHIT transcripts, none of the aberrant FHIT transcripts was observed in the matched normal tissue and colorectal adenoma tissue by nested RT-PCR assay.
  • The positive rate of FHIT gene expression in normal colorectal tissue, colorectal adenoma and carcinoma tissue was 93.75%, 68.75% and 46.25%, respectively.
  • CONCLUSION: The FHIT gene plays an important role in the regulation of apoptosis and decreased FHIT expression plays a key role in the initiation and progression of colorectal carcinoma.
  • [MeSH-major] Acid Anhydride Hydrolases / metabolism. Adenocarcinoma / metabolism. Adenoma / metabolism. Apoptosis / physiology. Colorectal Neoplasms / metabolism. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jan 1;60(1):18-21 [10646844.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):741-7 [16207476.001]
  • [Cites] Scand J Gastroenterol. 2000 Jun;35(6):637-41 [10912665.001]
  • [Cites] Mol Med. 2001 Jul;7(7):442-53 [11683369.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Cell. 1995 Jan 27;80(2):285-91 [7834748.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2936-9 [8674044.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9770-5 [8790406.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):504-12 [9012482.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):193-203 [9063739.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1981-5 [9157994.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2121-3 [9187107.001]
  • [Cites] Biochim Biophys Acta. 1997 Jun 7;1332(3):M65-70 [9196019.001]
  • [Cites] Jpn J Cancer Res. 1997 Apr;88(4):385-8 [9197530.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13771-6 [9391102.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cell. 1999 Jan 22;96(2):245-54 [9988219.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3866-9 [10463571.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):378-91 [15637400.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4685-8 [16094710.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1949-60 [10766185.001]
  • (PMID = 17373735.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4146863
  •  go-up   go-down


67. Sun Y, Tian H, Xiao FM, Xie XY, Song YG: [PI3K p85alpha expression and its role in the progression of colorectal cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):416-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PI3K p85alpha expression and its role in the progression of colorectal cancer].
  • OBJECTIVE: To investigate the expression of PI3K p85alpha in normal colorectal tissue, colorectal adenoma and primary colorectal carcinoma and explore its significance in the progression of colorectal cancer.
  • METHODS: The expression of PI3K p85alpha was detected in 116 normal colorectal tissue, colorectal adenoma and primary colorectal carcinoma specimens using immunohistochemical staining, and the relationship between the expression of PI3K p85alpha protein and the clinicopathological factors was analyzed.
  • RESULTS: The positivity rates of the expression of PI3K p85alpha protein increased gradually in the progression of colorectal cancer and showed significant differences between the tissues (P<0.05).
  • A significant difference was also noted in the positivity rates of the PI3K p85alpha expression in colorectal carcinoma tissues at different Dukes' stages (P<0.05).
  • CONCLUSIONS: Abnormal PI3K p85alpha expression occurs in the progression of colorectal cancer in close relation to the clinical stage, and the PI3K/AKT pathway plays an important role in the progression of colorectal cancer.
  • [MeSH-major] Carcinoma / enzymology. Colorectal Neoplasms / enzymology. Disease Progression. Phosphatidylinositol 3-Kinases / metabolism
  • [MeSH-minor] Adenoma / enzymology. Adenoma / pathology. Adult. Aged. Humans. Immunohistochemistry. Middle Aged. Signal Transduction. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304514.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


68. Ramadas A, Kandiah M: Food intake and colorectal adenomas: a case-control study in Malaysia. Asian Pac J Cancer Prev; 2009;10(5):925-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Food intake and colorectal adenomas: a case-control study in Malaysia.
  • It is well established that almost all colorectal cancers arise from benign, neoplastic adenomatous polyps.
  • In previous studies, intake of fruits, vegetables and legumes were found to decrease the risk for colorectal adenomas (CRA) and colorectal cancer.
  • In conclusion, our data support protective roles for soy, fruits and vegetables in the aetiology of colorectal adenomas and increase in risk in those with high intakes of red meat and tubers.
  • [MeSH-major] Adenoma / etiology. Adenoma / prevention & control. Colorectal Neoplasms / etiology. Colorectal Neoplasms / prevention & control. Diet. Eating

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104992.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


69. Bobe G, Sansbury LB, Albert PS, Cross AJ, Kahle L, Ashby J, Slattery ML, Caan B, Paskett E, Iber F, Kikendall JW, Lance P, Daston C, Marshall JR, Schatzkin A, Lanza E: Dietary flavonoids and colorectal adenoma recurrence in the Polyp Prevention Trial. Cancer Epidemiol Biomarkers Prev; 2008 Jun;17(6):1344-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary flavonoids and colorectal adenoma recurrence in the Polyp Prevention Trial.
  • Two recent case-control studies suggested that some flavonoid subgroups may play a role in preventing colorectal cancer.
  • The Polyp Prevention Trial was a randomized dietary intervention trial, which examined the effectiveness of a low-fat, high-fiber, high-fruit, and high-vegetable diet on adenoma recurrence.
  • Multivariate logistic regression models (adjusted for age, body mass index, sex, regular non-steroidal anti-inflammatory use, and dietary fiber intake) were used to estimate odds ratios and 95% confidence intervals for both any and advanced adenoma recurrence within quartiles of energy-adjusted flavonoid intake (baseline, during the trial, and change during the trial).
  • Total flavonoid intake was not associated with any or advanced adenoma recurrence.
  • However, high intake of flavonols, which are at greater concentrations in beans, onions, apples, and tea, was associated with decreased risk of advanced adenoma recurrence (4th versus 1st quartile during the trial; odds ratio, 0.24; 95% confidence interval, 0.11, 0.53; P(trend) = 0.0006).
  • Our data suggest that a flavonol-rich diet may decrease the risk of advanced adenoma recurrence.
  • [MeSH-major] Adenoma / prevention & control. Colorectal Neoplasms / prevention & control. Flavonoids / administration & dosage. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):684-93 [17416758.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1149-55 [10837003.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1655-60 [10964096.001]
  • [Cites] Am J Clin Nutr. 2001 Sep;74(3):387-401 [11522565.001]
  • [Cites] J Agric Food Chem. 2001 Oct;49(10):4924-9 [11600045.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):789-96 [11714106.001]
  • [Cites] Annu Rev Nutr. 2002;22:19-34 [12055336.001]
  • [Cites] Cancer Causes Control. 2002 May;13(4):373-82 [12074507.001]
  • [Cites] Am J Clin Nutr. 2002 Sep;76(3):560-8 [12198000.001]
  • [Cites] J Am Diet Assoc. 2002 Oct;102(10):1414-20 [12396158.001]
  • [Cites] Med Res Rev. 2003 Jul;23(4):519-34 [12710022.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 2:93-102 [14691983.001]
  • [Cites] Am J Clin Nutr. 2004 Feb;79(2):274-81 [14749234.001]
  • [Cites] Mol Pharmacol. 2004 Sep;66(3):683-93 [15322261.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1327-35 [2254769.001]
  • [Cites] Carcinogenesis. 1991 Jul;12(7):1193-6 [2070483.001]
  • [Cites] Nutr Cancer. 1993;20(1):21-9 [8415127.001]
  • [Cites] Nutr Cancer. 1993;20(3):199-204 [8108270.001]
  • [Cites] Cancer Lett. 1996 Jul 19;105(1):61-70 [8689634.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):375-83 [9162304.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):385-92 [9162305.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):118-21 [9075782.001]
  • [Cites] Am J Epidemiol. 1997 Aug 1;146(3):223-30 [9247006.001]
  • [Cites] Eur J Nutr. 1999 Feb;38(1):28-34 [10338685.001]
  • [Cites] Nutr Cancer. 1999;34(1):88-99 [10453447.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5636-45 [15533929.001]
  • [Cites] J Nutr Biochem. 2005 Mar;16(3):155-62 [15741050.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1450-6 [15831530.001]
  • [Cites] In Vivo. 2005 Sep-Oct;19(5):895-909 [16097445.001]
  • [Cites] J Med Food. 2005 Fall;8(3):281-90 [16176136.001]
  • [Cites] Crit Rev Food Sci Nutr. 2006;46(2):161-83 [16431408.001]
  • [Cites] J Nutr Biochem. 2006 Mar;17(3):165-76 [16169200.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3942-53 [16585224.001]
  • [Cites] J Nutr. 2006 Jul;136(7):1896-903 [16772456.001]
  • [Cites] Mol Cell Biochem. 2006 Jul;287(1-2):109-16 [16645725.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1555-8 [16896049.001]
  • [Cites] Nutr Cancer. 2006;54(2):243-51 [16898869.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2213-20 [16823841.001]
  • [Cites] Arch Pharm Res. 2006 Aug;29(8):633-44 [16964758.001]
  • [Cites] Am J Epidemiol. 2006 Oct 1;164(7):644-51 [16923774.001]
  • [Cites] J Nutr. 2007 May;137(5):1244-52 [17449588.001]
  • [Cites] Mol Carcinog. 2007 Jun;46(6):436-45 [17219438.001]
  • [Cites] J Am Coll Nutr. 2006 Oct;25(5):370-81 [17031005.001]
  • [Cites] J Agric Food Chem. 2006 Dec 13;54(25):9322-8 [17147414.001]
  • [Cites] J Agric Food Chem. 2006 Dec 27;54(26):9798-804 [17177504.001]
  • [Cites] J Nutr. 2007 Feb;137(2):391-8 [17237317.001]
  • [Cites] Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9 [17184768.001]
  • [Cites] J Agric Food Chem. 1999 Jun;47(6):2274-9 [10794622.001]
  • (PMID = 18559549.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010025-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids
  • [Other-IDs] NLM/ NIHMS56510; NLM/ PMC2517243
  •  go-up   go-down


70. Wu H, Dai Q, Shrubsole MJ, Ness RM, Schlundt D, Smalley WE, Chen H, Li M, Shyr Y, Zheng W: Fruit and vegetable intakes are associated with lower risk of colorectal adenomas. J Nutr; 2009 Feb;139(2):340-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fruit and vegetable intakes are associated with lower risk of colorectal adenomas.
  • Participants were part of the Tennessee Colorectal Polyp Study.
  • Cases had at least one adenoma and controls were polyp free.
  • Associations between dietary intakes and adenoma risk were evaluated using unconditional logistic regression with restricted cubic function spline.
  • In multivariate analyses of 764 cases and 1517 controls, increased intakes of total fruits, berries, fruit juice, and green leafy vegetables were associated with reduced adenoma risk.
  • This study provides additional evidence that high total fruit intake and certain fruit and vegetable intakes may be associated with a reduced risk of colorectal adenomas.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):403-10 [17574861.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1740-52 [11058617.001]
  • [Cites] Am J Epidemiol. 2000 Dec 1;152(11):1081-92 [11117618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jan;10(1):3-8 [11205486.001]
  • [Cites] Dig Dis Sci. 2001 Jan;46(1):86-95 [11270799.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):525-33 [11287446.001]
  • [Cites] Am J Epidemiol. 2002 Jun 15;155(12):1104-13 [12048224.001]
  • [Cites] Eur J Cancer Prev. 2002 Aug;11(4):369-75 [12195164.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):201-8 [12646508.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1161-8 [12973839.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):287-92 [14639617.001]
  • [Cites] Cancer Causes Control. 2003 Dec;14(10):959-70 [14750535.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2003 Dec;49(8):1295-304 [14984001.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):728-36 [14999782.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):10-25 [15199543.001]
  • [Cites] Nutr Cancer. 2004;49(2):131-8 [15489205.001]
  • [Cites] Int J Cancer. 1987 Aug 15;40(2):179-88 [3038756.001]
  • [Cites] Jpn J Cancer Res. 1990 Nov;81(11):1101-8 [2125036.001]
  • [Cites] Nutr Cancer. 1991;16(1):25-30 [1656394.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):884-91 [8388061.001]
  • [Cites] Int J Cancer. 1993 Sep 9;55(2):213-9 [8370618.001]
  • [Cites] Cancer Causes Control. 1995 Jul;6(4):292-302 [7548716.001]
  • [Cites] Epidemiology. 1995 Jul;6(4):356-65 [7548341.001]
  • [Cites] J Am Diet Assoc. 1996 Oct;96(10):1027-39 [8841165.001]
  • [Cites] Am J Epidemiol. 1996 Dec 1;144(11):1015-25 [8942431.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):56-61 [9212223.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Sep;6(9):661-70 [9298572.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):858-64 [9307184.001]
  • [Cites] Nutrition. 1999 Jun;15(6):523-6 [10378216.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1577-84 [15523086.001]
  • [Cites] Public Health Nutr. 2005 May;8(3):309-14 [15918928.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1619-25 [16030092.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2359-65 [16214917.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2789-95 [16393237.001]
  • [Cites] Chem Biol Interact. 2006 Mar 10;160(1):1-40 [16430879.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3942-53 [16585224.001]
  • [Cites] J Nutr. 2006 Jul;136(7):1896-903 [16772456.001]
  • [Cites] Am J Med. 2006 Sep;119(9):751-9 [16945610.001]
  • [Cites] J Nutr. 2007 Apr;137(4):999-1004 [17374667.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2408-9 [17551134.001]
  • [ErratumIn] J Nutr. 2010 Mar;140(3):667
  • (PMID = 19091801.001).
  • [ISSN] 1541-6100
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / CA095103-010005; United States / NCI NIH HHS / CA / R01 CA097386-01; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / R01CA97386; United States / NCI NIH HHS / CA / P50CA95103; United States / NCI NIH HHS / CA / CA097386-01; United States / NCI NIH HHS / CA / P50 CA095103-010005
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS92794; NLM/ PMC2646202
  •  go-up   go-down


71. Oka S, Tanaka S, Yoshida S, Hiyama T, Ueno Y, Ito M, Kitadai Y, Yoshihara M, Chayama K: A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas. Hiroshima J Med Sci; 2010 Mar;59(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A water-soluble extract from culture medium of Ganoderma lucidum mycelia suppresses the development of colorectal adenomas.
  • To confirm cancer-preventive effects of MAK, we performed a no-treatment concurrent controlled trial on patients with colorectal adenomas.
  • Patients who were determined to be carrying colorectal adenomas by colonoscopy were enrolled in this study.
  • Follow-up colonoscopy was performed after 12 months, and the colonoscopists recorded the size, site and macroscopic type of all adenomas.
  • The changes in the number of adenomas up to 12 months increased to 0.66 +/- 0.10 (mean +/- SE) in the control group, while decreasing in the MAK group to -0.42 +/- 0.10 (p < 0.01).
  • The total size of adenomas increased to 1.73 +/- 0.28 mm in the control group and decreased to -1.40 +/- 0.64 mm in the MAK group (p < 0.01).
  • The resultssuggest that MAK suppresses the development of colorectal adenomas - precancerous lesions of the large bowel.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Mycelium / metabolism. Precancerous Conditions / drug therapy. Reishi / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518254.001).
  • [ISSN] 0018-2052
  • [Journal-full-title] Hiroshima journal of medical sciences
  • [ISO-abbreviation] Hiroshima J. Med. Sci.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Culture Media, Conditioned; 059QF0KO0R / Water
  •  go-up   go-down


72. Skjelbred CF, Saebø M, Wallin H, Nexø BA, Hagen PC, Lothe IM, Aase S, Johnson E, Hansteen IL, Vogel U, Kure EH: Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study. BMC Cancer; 2006 Mar 16;6:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control study.
  • For colorectal cancer the importance of mutations in mismatch repair genes has been extensively documented.
  • Less is known about other DNA repair pathways in colorectal carcinogenesis.
  • METHODS: We used a case-control study design (157 carcinomas, 983 adenomas and 399 controls) to test the association between five polymorphisms in these DNA repair genes (XRCC1 Arg194Trp, Arg280His, Arg399Gln, XRCC3 Thr241Met and XPD Lys751Gln), and risk of colorectal adenomas and carcinomas in a Norwegian cohort.
  • RESULTS: The XRCC1 280His allele was associated with an increased risk of adenomas (OR 2.30, 95% CI 1.19-4.46).
  • The XRCC1 399Gln allele was associated with a reduction of risk of high-risk adenomas (OR 0.62, 95% CI 0.41-0.96).
  • Carriers of the variant XPD 751Gln allele had an increased risk of low-risk adenomas (OR 1.40, 95% CI 1.03-1.89), while no association was found with risk of carcinomas.
  • CONCLUSION: Our results suggest an increased risk for advanced colorectal neoplasia in individuals with the XRCC1 Arg280His polymorphism and a reduced risk associated with the XRCC1 Arg399Gln polymorphism.
  • Interestingly, individuals with the XPD Lys751Gln polymorphism had an increased risk of low-risk adenomas.
  • This may suggest a role in regression of adenomas.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic. Xeroderma Pigmentosum Group D Protein / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):757-61 [11025669.001]
  • [Cites] Cancer Lett. 2000 Oct 16;159(1):79-86 [10974409.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):119-23 [11219768.001]
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1437-45 [11532866.001]
  • [Cites] Pharmacogenetics. 2002 Mar;12(2):145-50 [11875368.001]
  • [Cites] Hum Mol Genet. 2002 Jun 1;11(12):1399-407 [12023982.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):939-43 [12223443.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):201-10 [12427539.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1332-52 [12433710.001]
  • [Cites] Mutagenesis. 2002 Nov;17(6):463-9 [12435843.001]
  • [Cites] Nature. 1993 Oct 28;365(6449):852-5 [8413672.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Gut. 1996 Sep;39(3):449-56 [8949653.001]
  • [Cites] Curr Opin Genet Dev. 1997 Apr;7(2):158-69 [9115419.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):604-8 [9485007.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1357-66 [10064601.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):207-19 [10064862.001]
  • [Cites] Genes Dev. 1999 Apr 1;13(7):768-85 [10197977.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 [10359544.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2557-61 [10363972.001]
  • [Cites] Mutat Res. 1999 Jun 23;434(2):75-88 [10422536.001]
  • [Cites] Biochem Genet. 2004 Dec;42(11-12):453-60 [15587988.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):1-14 [15615908.001]
  • [Cites] BMC Cancer. 2005 Jan 28;5:12 [15679883.001]
  • [Cites] Mutat Res. 2005 Apr 4;582(1-2):135-45 [15781218.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):428-32 [15800946.001]
  • [Cites] Cancer Lett. 2005 Nov 8;229(1):85-91 [15946795.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Nov;163(1):38-43 [16271954.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1231-50 [12704570.001]
  • [Cites] Carcinogenesis. 2003 May;24(5):899-904 [12771034.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):584-5 [12815008.001]
  • [Cites] Scand J Gastroenterol. 2003 Jun;38(6):635-42 [12825872.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):333-7 [12865926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1168-74 [14652276.001]
  • [Cites] Mutat Res. 2004 Feb 26;546(1-2):65-74 [14757194.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1090-1 [15184273.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):633-9 [15239144.001]
  • [Cites] Cancer Lett. 2004 Sep 15;213(1):67-72 [15312685.001]
  • [Cites] Scand J Gastroenterol. 1986 Sep;21(7):853-62 [3775252.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):261-5 [1729695.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5612-6 [11059748.001]
  • (PMID = 16542436.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; 0 / X-ray repair cross complementing protein 3; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  • [Other-IDs] NLM/ PMC1458350
  •  go-up   go-down


73. Rubie C, Frick VO, Wagner M, Schuld J, Gräber S, Brittner B, Bohle RM, Schilling MK: ELR+ CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer; 2008;8:178
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ELR+ CXC chemokine expression in benign and malignant colorectal conditions.
  • Here, we comparatively analyzed their expression profile in resection specimens from patients with colorectal adenoma (CRA) (n = 30) as well as colorectal carcinoma (CRC) (n = 48) and corresponding colorectal liver metastases (CRLM) (n = 16).
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Chemokines, CXC / biosynthesis. Colorectal Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytokine. 2000 Jan;12(1):78-85 [10623446.001]
  • [Cites] World J Gastroenterol. 2007 Oct 7;13(37):4996-5002 [17854143.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] Oncogene. 2000 Jul 20;19(31):3477-86 [10918606.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1706-12 [10959056.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] J Virol. 2001 Jul;75(13):5812-22 [11390582.001]
  • [Cites] J Intern Med. 2001 Aug;250(2):91-104 [11489059.001]
  • [Cites] Scand J Gastroenterol. 2001 Aug;36(8):854-64 [11495082.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3968-74 [11502840.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91 [11544106.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1405-14 [11583968.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3298-304 [11595728.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):9-18 [12101257.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2853-60 [14978086.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1853-60 [14996749.001]
  • [Cites] Chest. 2004 May;125(5 Suppl):133S [15136463.001]
  • [Cites] Curr Opin Oncol. 1991 Feb;3(1):75-92 [2043698.001]
  • [Cites] J Exp Med. 1991 Dec 1;174(6):1355-62 [1744577.001]
  • [Cites] Cytokines. 1992;4:96-116 [1335322.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27348-57 [7592998.001]
  • [Cites] Comput Methods Programs Biomed. 1995 Dec;48(3):257-62 [8925653.001]
  • [Cites] J Immunol. 1997 Jun 1;158(11):5257-66 [9164944.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] J Leukoc Biol. 1997 Nov;62(5):588-97 [9365113.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):436-45 [9459648.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):465-72 [9691082.001]
  • [Cites] J Immunol Methods. 1998 Nov 1;220(1-2):1-17 [9839921.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] Exp Cell Res. 2005 Feb 15;303(2):331-42 [15652347.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3581-4 [16101183.001]
  • [Cites] Dig Dis Sci. 2006 Jan;51(1):173-7 [16416232.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):768-78 [16510280.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Tumour Biol. 2006;27(3):166-74 [16641550.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):468-77 [16764701.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1936-41 [16721367.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):221-7 [16458421.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5951-9 [17062666.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):87-96 [17275174.001]
  • [Cites] J Leukoc Biol. 2000 Jan;67(1):53-62 [10647998.001]
  • (PMID = 18578857.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL1 protein, human; 0 / CXCL5 protein, human; 0 / CXCL6 protein, human; 0 / Chemokine CXCL1; 0 / Chemokine CXCL5; 0 / Chemokine CXCL6; 0 / Chemokines, CXC; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2459188
  •  go-up   go-down


74. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, Agami R: Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res; 2008 Jul 15;68(14):5795-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer.
  • Inactivation of the adenomatous polyposis coli (APC) gene is a major initiating event in colorectal tumorigenesis.
  • Interestingly, we find a considerable up-regulation of miR-135a&b in colorectal adenomas and carcinomas, which significantly correlated with low APC mRNA levels.
  • Thus, our results uncover a miRNA-mediated mechanism for the control of APC expression and Wnt pathway activity, and suggest its contribution to colorectal cancer pathogenesis.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / genetics. Adenomatous Polyposis Coli Protein / physiology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics


75. van den Donk M, Visker MH, Harryvan JL, Kok FJ, Kampman E: Dietary intake of B-vitamins, polymorphisms in thymidylate synthase and serine hydroxymethyltransferase 1, and colorectal adenoma risk: a Dutch case-control study. Cancer Lett; 2007 May 18;250(1):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary intake of B-vitamins, polymorphisms in thymidylate synthase and serine hydroxymethyltransferase 1, and colorectal adenoma risk: a Dutch case-control study.
  • In a case-control study, including 768 cases and 709 controls, we investigated the associations between colorectal adenomas and TS tandem repeat and SHMT1 C1420T polymorphisms, and the interplay with B-vitamins.
  • The polymorphisms were not associated with adenomas, but there was a borderline significant interaction between TS genotype and vitamin B6: the association between vitamin B6 and adenomas seemed positive in TS 3R/3R individuals, but inverse in TS 2R/2R individuals.
  • This study does not provide evidence for a role of SHMT1 genotype in adenoma occurrence.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Diet. Glycine Hydroxymethyltransferase / genetics. Polymorphism, Genetic. Thymidylate Synthase / genetics. Vitamin B Complex

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • Hazardous Substances Data Bank. Riboflavin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17113224.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 12001-76-2 / Vitamin B Complex; 8059-24-3 / Vitamin B 6; 935E97BOY8 / Folic Acid; EC 2.1.1.45 / Thymidylate Synthase; EC 2.1.2.1 / Glycine Hydroxymethyltransferase; EC 2.1.2.1 / SHMT protein, human; P6YC3EG204 / Vitamin B 12; TLM2976OFR / Riboflavin
  •  go-up   go-down


76. Bugni JM, Meira LB, Samson LD: Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. Oncogene; 2009 Feb 5;28(5):734-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MGMT expression is lost by epigenetic silencing in a variety of human cancers including nearly half of sporadic colorectal cancers, suggesting that this loss maybe causal.
  • Using mice with a targeted disruption of the Mgmt gene, we tested whether Mgmt protects against azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF), against AOM and dextran sulfate sodium (DSS)-induced colorectal adenomas and against spontaneous intestinal adenomas in Apc(Min) mice.
  • In addition, following AOM+DSS treatment Mgmt protected against adenoma formation to the same degree as it protected against AOM-induced ACF formation.
  • Finally, Mgmt deficiency did not affect spontaneous intestinal adenoma development in Apc(Min/+) mice, suggesting that Mgmt suppresses intestinal cancer associated with exogenous alkylating agents, and that endogenous alkylation does not contribute to the rapid tumor development seen in Apc(Min/+) mice.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1991 Nov 25;19(22):6163-7 [1956775.001]
  • [Cites] Mutat Res. 1985 Jun-Jul;150(1-2):77-84 [4000169.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6471-5 [1423294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2117-21 [7681584.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6424-8 [8341649.001]
  • [Cites] Epithelial Cell Biol. 1992 Oct;1(4):147-55 [1307946.001]
  • [Cites] Carcinogenesis. 1995 Mar;16(3):451-6 [7697797.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):2922-6 [8674041.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13629-34 [8942985.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2415-8 [9192819.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1561-7 [9276631.001]
  • [Cites] Cell. 1997 Nov 14;91(4):467-77 [9390556.001]
  • [Cites] Mutat Res. 1997 Nov 28;381(2):227-41 [9434879.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1087-9 [9515784.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5116-20 [9560238.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):127-42 [10064856.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1301-7 [10096563.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3911-5 [10097137.001]
  • [Cites] Mutagenesis. 1999 May;14(3):339-47 [10375003.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10764-9 [10485900.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8876-81 [15604247.001]
  • [Cites] Biochemistry. 2005 Nov 22;44(46):15396-405 [16285744.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):68-75 [16436636.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):335-46 [16612326.001]
  • [Cites] Oncology. 2006;71(1-2):124-30 [17347588.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] Carcinogenesis. 1999 Dec;20(12):2355-60 [10590233.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):593-8 [10753191.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7934-42 [11691815.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8435-40 [11731424.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2092-7 [11929830.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):823-30 [12016156.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8927-31 [12060718.001]
  • [Cites] Science. 2002 Jul 19;297(5580):403-5 [12130785.001]
  • [Cites] Biochem Pharmacol. 2003 Oct 15;66(8):1547-54 [14555233.001]
  • [Cites] DNA Repair (Amst). 2004 Aug-Sep;3(8-9):1091-101 [15279797.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):5931-40 [15208683.001]
  • [Cites] J Biol Chem. 1984 Jul 10;259(13):8095-100 [6376499.001]
  • [Cites] Carcinogenesis. 1984 Aug;5(8):1061-4 [6744514.001]
  • [Cites] Nucleic Acids Res. 1992 Jun 25;20(12):2933-40 [1620587.001]
  • (PMID = 19029948.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES02109; United States / NCI NIH HHS / CA / P30 CA014051; United States / NIEHS NIH HHS / ES / P30 ES002109; United States / NCI NIH HHS / CA / CA14051; United States / NCI NIH HHS / CA / CA75576; United States / NCI NIH HHS / CA / R01 CA075576
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Carcinogens; 0 / DNA-Binding Proteins; 0 / Msh6 protein, mouse; 0 / Tumor Suppressor Proteins; 9042-14-2 / Dextran Sulfate; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, mouse; EC 6.5.1.- / DNA Repair Enzymes; MO0N1J0SEN / Azoxymethane
  • [Other-IDs] NLM/ NIHMS74471; NLM/ PMC3557788
  •  go-up   go-down


77. Pequin P, Manfredi S, Quentin V, Heresbach D, Boyer J, Siproudhis L, Bretagne JF: Patients with sporadic duodenal adenoma are a high-risk group for advanced colorectal neoplasia: results of a case-control study. Aliment Pharmacol Ther; 2007 Jul 15;26(2):277-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with sporadic duodenal adenoma are a high-risk group for advanced colorectal neoplasia: results of a case-control study.
  • AIM: To evaluate colorectal cancer risk among patients with sporadic duodenal neoplasia using a case-control protocol.
  • METHODS: Cases were 35 patients referred for the management of sporadic duodenal adenoma and who underwent colonoscopy.
  • Colonoscopy findings among cases were compared with those from a control group matched for age and sex (two controls per case) without duodenal adenoma.
  • Colonoscopy findings were categorized as adenoma, advanced adenoma, cancer or advanced neoplasia.
  • RESULTS: Colorectal adenoma was present in 31% of cases vs. 24% of controls, advanced neoplasia in 29% vs. 4%, advanced adenoma in 23% vs. 3% and adenocarcinoma in 6% vs. 1%.
  • The relative risks of advanced colorectal adenoma and advanced colorectal neoplasia in cases were 10.1 (95% CI: 1.8-100.1, P = 0.003) and 8.9 (95% CI: 2.1-53.3, P = 0.001), respectively.
  • CONCLUSIONS: The relative risk of advanced colorectal adenoma and advanced neoplasia in cases was nine- to 10-fold that among controls.
  • Patients with sporadic duodenal adenoma represent a high-risk group for advanced colorectal neoplasia and should therefore undergo complete colonoscopy.
  • [MeSH-major] Adenoma / pathology. Colonoscopy. Colorectal Neoplasms / diagnosis. Duodenal Neoplasms / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593073.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Wagner PL, Chen YT, Yantiss RK: Immunohistochemical and molecular features of sporadic and FAP-associated duodenal adenomas of the ampullary and nonampullary mucosa. Am J Surg Pathol; 2008 Sep;32(9):1388-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and molecular features of sporadic and FAP-associated duodenal adenomas of the ampullary and nonampullary mucosa.
  • The pathogenesis of duodenal adenomas is not well elucidated.
  • Much of the literature pertains to ampullary adenomas and those associated with familial adenomatous polyposis (FAP).
  • In this study, we evaluated the molecular features of a series of sporadic duodenal adenomas (n=22) that developed distal to the ampulla, and compared them with the features of sporadic ampullary adenomas (n=9) and FAP-related polyps (n=12).
  • Wnt signaling pathway abnormalities occurred in sporadic, nonampullary (82%), and ampullary (77%) adenomas at comparable rates, usually reflecting nuclear beta-catenin immunostaining (64% and 44%, respectively), and APC rather than beta-catenin, mutations.
  • KRAS mutations were infrequent in sporadic, nonampullary adenomas (18%), and FAP-related adenomas (9%); moderately frequent in ampullary adenomas (44%); and none of the cases harbored BRAF mutations.
  • Only 4 (13%) sporadic adenomas showed nuclear p53 staining, but no p53 mutations were detected in exons 5 to 8.
  • Loss of O-methylguanine methyltransferase immunostaining was identified in 1 sporadic, nonampullary adenoma, and none of the polyps in any group showed loss of MLH-1, MSH-2, or MSH-6 staining, or high-frequency microsatellite instability.
  • We conclude that sporadic and FAP-related adenomas show similar molecular features, regardless of their anatomic location.
  • Similar to colorectal adenomas, they harbor APC and KRAS mutations; but BRAF mutations, p53 alterations, and DNA mismatch repair abnormalities are rare.
  • [MeSH-major] Adenoma / genetics. Adenoma / metabolism. Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / metabolism. Duodenal Neoplasms / genetics. Duodenal Neoplasms / metabolism


79. Johnson V, Lipton LR, Cummings C, Eftekhar Sadat AT, Izatt L, Hodgson SV, Talbot IC, Thomas HJ, Silver AJ, Tomlinson IP: Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families. J Med Genet; 2005 Oct;42(10):756-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
  • OBJECTIVE: To analyse somatic molecular changes, clinicopathological features, family history, and germline mutations in families with colorectal cancer (CRC).
  • METHODS: Molecular changes (K-ras and beta-catenin mutations, chromosome 18q allele loss (LOH), APC LOH, microsatellite instability (MSI), and expression of beta-catenin and p53) were examined in four series of CRC patients with proven or probable hereditary disease: hereditary non-polyposis colon cancer (HNPCC); MYH associated polyposis (MAP); multiple (>5) colorectal adenomas without familial adenomatous polyposis (FAP); and other families/cases referred to family cancer clinics (FCC series).
  • RESULTS: There was overlap between genetic pathways followed by each type of CRC, but significant differences included: increased frequency of K-ras mutation and reduced frequency of APC LOH in cancers from MAP, but not from multiple adenoma patients; reduced frequency of LOH in HNPCC CRCs; and increased MSI in CRCs from HNPCC, but not from FCC or multiple adenoma patients.
  • Cancers from the FCC, unselected, and multiple adenoma series shared similar molecular characteristics.
  • In the FCC and multiple adenoma series, hierarchical cluster analysis using the molecular features of the cancers consistently identified two distinct groups, distinguished by presence or absence of K-ras mutation.
  • CONCLUSIONS: While K-ras mutation status is known to differentiate hereditary bowel cancer syndromes such as MAP and FAP, it may also distinguish groups of non-HNPCC, FCC patients whose disease has different, as yet unknown, genetic origins.
  • [MeSH-major] Colorectal Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Genetic Predisposition to Disease. Germ-Line Mutation

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Feb 24;24(9):1542-51 [15674332.001]
  • [Cites] Gut. 2005 Feb;54(2):264-7 [15647192.001]
  • [Cites] Br J Cancer. 2000 May;82(10):1689-93 [10817505.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9719-23 [11481457.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):823-7 [11857362.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):858-66 [11978509.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):791-9 [12606733.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7595-9 [14633673.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):191-5 [14734469.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7166-73 [1977514.001]
  • [Cites] Am J Hum Genet. 1993 Feb;52(2):263-72 [8381579.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3011-20 [8187091.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Gastroenterology. 1996 Aug;111(2):307-17 [8690195.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):664-9 [9421366.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4934-43 [15611508.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):118-29 [15531920.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2225-8 [10681434.001]
  • (PMID = 15788729.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1735937
  •  go-up   go-down


80. Flood A, Peters U, Jenkins DJ, Chatterjee N, Subar AF, Church TR, Bresalier R, Weissfeld JL, Hayes RB, Schatzkin A, Prostate, Lung, Colorectal, Ovarian (PLCO) Project Team: Carbohydrate, glycemic index, and glycemic load and colorectal adenomas in the Prostate, Lung, Colorectal, and Ovarian Screening Study. Am J Clin Nutr; 2006 Nov;84(5):1184-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate, glycemic index, and glycemic load and colorectal adenomas in the Prostate, Lung, Colorectal, and Ovarian Screening Study.
  • BACKGROUND: It is possible that high-glycemic-load diets, through their hyperinsulinemic effects, can increase the risk of colorectal cancer.
  • OBJECTIVE: We analyzed data from a cancer screening study to determine whether persons with high-glycemic-load diets would be at an increased risk of distal adenomas.
  • DESIGN: We included subjects with no prior adenoma or cancer from the Prostate, Lung, Colorectal, and Ovarian screening trial and whose results from flexible sigmoidoscopy exams indicated either no lesions (n = 34 817) or >/=1 distal adenoma (n = 3696).
  • Using logistic regression analysis, we calculated, separately for men and women, prevalence odds ratios (ORs) and 95% CIs of sigmoidoscopy-detected, distal adenomas for quintiles of energy-adjusted dietary carbohydrate, glycemic index, and glycemic load.
  • CONCLUSION: Despite expectations that increasing glycemic load and glycemic index would increase the risk of adenoma, we observed no association in women and even an inverse association in men.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Dietary Carbohydrates / administration & dosage. Food Habits
  • [MeSH-minor] Adenomatous Polyps / diagnosis. Adenomatous Polyps / epidemiology. Adenomatous Polyps / etiology. Aged. Case-Control Studies. Cohort Studies. Confidence Intervals. Female. Glycemic Index. Humans. Hyperglycemia / complications. Logistic Models. Male. Mass Screening. Middle Aged. Multivariate Analysis. Nutrition Assessment. Odds Ratio. Risk Assessment. Risk Factors. Sigmoidoscopy. Surveys and Questionnaires. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Carbohydrates.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17093173.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K07-CA108910-01A1
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Carbohydrates
  •  go-up   go-down


81. Risio M, Malacarne D, Giaretti W: KRAS transitions and villous growth in colorectal adenomas. Cell Oncol; 2005;27(5-6):363-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS transitions and villous growth in colorectal adenomas.
  • [MeSH-major] Adenoma / genetics. Adenoma, Villous / genetics. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Genes, ras

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16373972.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4617505
  •  go-up   go-down


82. Dorval E, Jankowski JM, Barbieux JP, Viguier J, Bertrand P, Brondin B, Bougnoux P, Corpet DE, Association Gastro 37: Polyethylene glycol and prevalence of colorectal adenomas. Gastroenterol Clin Biol; 2006 Oct;30(10):1196-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyethylene glycol and prevalence of colorectal adenomas.
  • This study tests the hypothesis that use of a PEG-based laxative might reduce the prevalence of colorectal tumors.
  • Age, gender, previous polyps, family history of colorectal cancer, constipation, digestive symptoms were also recorded.
  • Among those, 813 had no tumor, 329 had adenomas, and 23 had carcinomas.
  • In a univariate analysis, older age, male gender, lack of digestive symptom, and previous polyps were more common in patients with colorectal tumors.
  • In multivariate analysis, older age and male gender were associated with higher risk, and NSAIDs use with lower risk, of colorectal tumors.
  • CONCLUSION: Forlax users had a halved risk of colorectal tumors in univariate analysis, which suggests that PEG may prevent carcinogenesis.
  • [MeSH-major] Adenoma / epidemiology. Cathartics / therapeutic use. Colorectal Neoplasms / epidemiology. Polyethylene Glycols / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075478.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cathartics; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


83. Tao H, Shinmura K, Suzuki M, Kono S, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N, Sugimura H: Association between genetic polymorphisms of the base excision repair gene MUTYH and increased colorectal cancer risk in a Japanese population. Cancer Sci; 2008 Feb;99(2):355-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between genetic polymorphisms of the base excision repair gene MUTYH and increased colorectal cancer risk in a Japanese population.
  • Biallelic germline mutations of MUTYH have been shown to predict familial and sporadic multiple colorectal adenomas and carcinomas, however, whether there is an association between single nucleotide polymorphisms (SNPs) of MUTYH and sporadic colorectal cancer (CRC) risk has remained unclear.
  • [MeSH-major] Colorectal Neoplasms / genetics. DNA Glycosylases / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18271935.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


84. Takahashi T, Shigematsu H, Shivapurkar N, Reddy J, Zheng Y, Feng Z, Suzuki M, Nomura M, Augustus M, Yin J, Meltzer SJ, Gazdar AF: Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer; 2006 Feb 15;118(4):924-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers.
  • The aims of our study were to study the role of methylation of a large panel of genes during multistage pathogenesis and to correlate our findings with patient age and other clinico-pathological features.
  • We investigated the aberrant promoter methylation profile of 19 genes in 92 colorectal cancers (CRCs) and corresponding nonmalignant epithelia (NME) (n = 57), and selected 15 genes for studying 26 colorectal adenomas (CAs).

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] NIH Guide Grants Contracts. 2014 Nov 14;:NOT-OD-15-022 [25412515.001]
  • [RetractionIn] Int J Cancer. 2013 Jan 15;132(2):499 [23169200.001]
  • [CommentIn] Fed Regist. 2014 Sep 18;79(181):56075-56076 [27737247.001]
  • (PMID = 16108009.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U01CA8497102; United States / NCI NIH HHS / CA / CA01808; United States / NCI NIH HHS / CA / CA098450; United States / NCI NIH HHS / CA / CA77057; United States / NCI NIH HHS / CA / CA85069; United States / NCI NIH HHS / CA / CA95323
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Retracted Publication
  • [Publication-country] United States
  •  go-up   go-down


85. Paun BC, Kukuruga D, Jin Z, Mori Y, Cheng Y, Duncan M, Stass SA, Montgomery E, Hutcheon D, Meltzer SJ: Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. Cancer; 2010 Oct 1;116(19):4495-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas.
  • BACKGROUND: Colorectal cancer (CRC) is 1 of the leading causes of death in the Western world.
  • CRC develops from premalignant lesions, chiefly colorectal adenomas.
  • Currently, the most accurate and recommended screening method for finding colorectal adenomas is colonoscopy performed on all individuals aged>50 years.
  • The objectives of the current study were to correlate epigenetic alterations that occur in normal rectal mucosa, smoking status, and age with the presence or absence of concomitant colorectal adenomas and to assess the potential clinical value of methylation in normal rectal biopsies as a screening assay for the presence of polyps and, hence, the need for a full colonoscopy.
  • RESULTS: By using several sets of genes, clinical characteristics, and multivariate analyses, the authors developed a prediction model for the presence of concomitant colorectal adenomas at the time of rectal biopsy.
  • They also observed strong correlations between smoking status and rectal methylation pattern and between smoking status and the presence or risk of concomitant adenomas.
  • CONCLUSIONS: A prediction model was developed for the presence of colorectal adenomas based on gene methylation patterns in the normal rectum.
  • The results indicated that these genes may be involved in early stages of adenoma formation.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1460-1 [10995795.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2009 Sep;12(5):539-43 [19512917.001]
  • [Cites] J Gastroenterol. 2000;35(10):727-34 [11063215.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1361-71 [12651628.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] Rom J Gastroenterol. 2004 Sep;13(3):187-93 [15470530.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):661-8 [923394.001]
  • [Cites] Nature. 1983 Jan 6;301(5895):89-92 [6185846.001]
  • [Cites] Biochem Biophys Res Commun. 1983 Feb 28;111(1):47-54 [6187346.001]
  • [Cites] Science. 1985 Apr 12;228(4696):187-90 [2579435.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • [Cites] Gastroenterology. 1993 May;104(5):1445-51 [8482454.001]
  • [Cites] Eur J Cancer Prev. 1993 Jun;2 Suppl 2:83-7 [8364377.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] Cancer Res. 1995 Dec 15;55(24):6063-70 [8521394.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):740-3 [15767361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13580-5 [16174748.001]
  • [Cites] J Nutr. 2006 Nov;136(11):2748-53 [17056795.001]
  • [Cites] Dig Dis Sci. 2007 Jun;52(6):1462-70 [17372834.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2128-35 [17932361.001]
  • [Cites] BMC Cancer. 2008;8:87 [18380902.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):227-235.e3 [18992744.001]
  • [Cites] Gut. 2000 Nov;47(5):689-93 [11034586.001]
  • (PMID = 20572039.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077057-06; United States / NCI NIH HHS / CA / CA095323-09A2; United States / NIDDK NIH HHS / DK / R01 DK047717; United States / NCI NIH HHS / CA / CA077057-06; United States / NIDDK NIH HHS / DK / DK047717-07; United States / NCI NIH HHS / CA / R01 CA095323-09A2; United States / NCI NIH HHS / CA / R01 CA077057; United States / NCI NIH HHS / CA / R01 CA095323; United States / NIDDK NIH HHS / DK / R01 DK047717-07
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS251065; NLM/ PMC2988654
  •  go-up   go-down


86. Zhongyin Z, Hesheng L, Jun L, Jihong C: Association of serum lipids and apolipoprotein E gene polymorphism with the risk of colorectal adenomas. Saudi Med J; 2006 Feb;27(2):161-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of serum lipids and apolipoprotein E gene polymorphism with the risk of colorectal adenomas.
  • OBJECTIVE: To investigate the relationship of serum lipids and apolipoprotein (apoE) gene polymorphism to colorectal adenomas.
  • Ninety-eight patients with colorectal adenomas and 40 healthy subjects were enrolled, and their serum levels of triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were determined.
  • RESULTS: Serum TC levels of colorectal adenomas group (5.32 +/- 0.85 mmol/L), distal colorectal adenomas group (5.58 +/- 0.63 mmol/L), and villous adenoma group (5.49 +/- 0.69 mmol/L) were higher than the control group (4.28 +/- 0.62 mmol/L, p=0.016), proximal colorectal adenomas group (4.82 +/- 0.58 mmol/L, p=0.038) and non-villous adenoma group (4.76 +/- 0.58 mmol/L, p=0.03).
  • Serum HDL-C levels of colorectal adenomas group (1.39 +/- 0.25 mmol/L) were lower than the control group (1.51 +/- 0.29 mmol/L) (p=0.035).
  • Serum lipids levels of each genotype in colorectal adenomas group were not statistically significant.
  • Apolipoprotein E3/E4 genotypic frequency in colorectal adenomas group (7.1%) was lower than the control group (17.5%) (p=0.012).
  • CONCLUSION: The findings suggest that altered lipid metabolism may be differentially associated with colorectal adenomas and the persons with apoE E3/E4 genotype have lower risk suffering from colorectal adenomas than those with other genotypes.
  • [MeSH-major] Adenoma / blood. Adenoma / genetics. Apolipoproteins E / genetics. Colorectal Neoplasms / blood. Colorectal Neoplasms / genetics. Lipids / blood

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501668.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Lipids; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


87. Castellví-Bel S, Balaguer F, Castells A: [MYH and colorectal cancer. A significant advance?]. Gastroenterol Hepatol; 2006 Aug-Sep;29(7):409-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MYH and colorectal cancer. A significant advance?].
  • Colorectal cancer is the second most common neoplasm and the second most frequent cause of cancer-related deaths in Spain.
  • Colorectal polyposis associated with mutations in the MYH gene is an autosomal recessive syndrome characterized by the development of colorectal adenomas and cancer.
  • [MeSH-minor] Base Pair Mismatch / genetics. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / genetics. Epidemiologic Studies. Genetic Predisposition to Disease. Humans. Myosin Heavy Chains / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938257.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / MYH16 protein, human; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase; EC 3.6.4.1 / Myosin Heavy Chains
  • [Number-of-references] 29
  •  go-up   go-down


88. Guilera M, Connelly-Frost A, Keku TO, Martin CF, Galanko J, Sandler RS: Does physical activity modify the association between body mass index and colorectal adenomas? Nutr Cancer; 2005;51(2):140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does physical activity modify the association between body mass index and colorectal adenomas?
  • Although both physical inactivity and obesity have been associated with an increased risk of colorectal adenomas, it is unclear whether physical activity modifies the relationship between obesity and colorectal adenomas or through what mechanism this might occur.
  • The aim of this study is to evaluate whether physical activity modifies the relationship between body mass index (BMI) and colorectal adenomas and whether apoptosis is a plausible mechanism responsible for this effect modification.
  • Study subjects were part of a large, cross-sectional study, the Diet and Health Study III.
  • There were 226 patients with adenomas and 494 adenoma-free controls.
  • When comparing overweight subjects with the referent group (high physical activity/normal BMI), the relative odds of having an adenoma decreased as physical activity increased: low (odds ratio, OR=1.6; 95% confidence interval, CI=0.7-3.4); moderate (OR=1.1; 95% CI=0.6-2.0); and high (OR=0.8; 95% CI=0.4-1.6).
  • When comparing obese subjects with the referent group, relative odds of having an adenoma were increased regardless of physical activity level.
  • Our results suggest that physical activity may modify the association between obesity and colorectal adenoma until a high level of obesity is achieved.
  • [MeSH-major] Adenoma / epidemiology. Body Mass Index. Colorectal Neoplasms / epidemiology. Motor Activity / physiology. Obesity / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860435.001).
  • [ISSN] 0163-5581
  • [Journal-full-title] Nutrition and cancer
  • [ISO-abbreviation] Nutr Cancer
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK34987; United States / NCI NIH HHS / CA / R01 CA44684; United States / NIDDK NIH HHS / DK / T32 DK07634
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


89. Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, Hawk E, Pinsky PF: A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol; 2009 May;7(5):568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Aberrant crypt foci (ACF) are the putative precursor of colorectal adenomas.
  • METHODS: Subjects from the Prostate, Lung, Colorectal and Ovarian cancer screening trial were recruited for an ACF study, with subjects with adenoma history being oversampled.
  • RESULTS: A total of 505 (66% male; 55% > or =70 y) subjects from 4 institutions were examined; 42% had no adenoma, 32% had nonadvanced distal adenoma, and 25% had advanced distal adenoma at the baseline Prostate, Lung, Colorectal and Ovarian cancer screening trial examination (8.2 years before ACF examination on average).
  • Baseline adenoma status was not associated with ACF prevalence (range, 66%-69%) or mean number of ACF (range, 3.1-3.5).
  • Age, sex, family history of colorectal cancer, and aspirin/nonsteroidal anti-inflammatory drug use were not associated significantly with ACF prevalence.
  • CONCLUSIONS: ACF prevalence and number were not associated with adenoma history, and only 68.5% of endoscopic ACF were confirmed histologically.
  • These results raise concern about the use of ACF as a surrogate marker of colorectal cancer risk.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418605.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CN25404; United States / NCI NIH HHS / CN / N01-CN2551
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


90. Becker F, Nusko G, Welke J, Hahn EG, Mansmann U: Benefit-risk analysis of different risk-related surveillance schedules following colorectal polypectomy. Hepatogastroenterology; 2007 Dec;54(80):2249-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benefit-risk analysis of different risk-related surveillance schedules following colorectal polypectomy.
  • BACKGROUND/AIMS: For colorectal screening patients a gain of life time was previously calculated to be about 30-50 days.
  • Different recommendations for recognizing at-risk groups and defining surveillance intervals after an initial finding of colorectal adenomas have been published.
  • METHODOLOGY: A Markov model based on time-dependent transition possibilities was developed to compare two surveillance schedules: recommendations based on the Erlangen Registry of Colorectal Polyps (ERCRP) and the National Polyp Study (NPS).
  • The data used in this model were taken from different sources, namely the ERCRP, the German Study Group of Colorectal Cancer, the German Statistical Yearbook, and from meta-analyses of studies reporting data on complications and sensitivity of colonoscopy.
  • Approximately 84% and 79% of deaths from colorectal carcinoma (CRC) could be prevented if patients were followed up according to the recommendations of the ERCRP and the NPS, respectively.
  • CONCLUSIONS: Surveillance using colonoscopy is an effective tool for preventing CRC after colorectal polypectomy and similar to the screening procedure.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Colonic Polyps / surgery. Colonoscopy. Continuity of Patient Care / standards. Outcome Assessment (Health Care). Risk Assessment

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265643.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


91. Daniel P, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska O, Malecka-Panas E: Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int J Colorectal Dis; 2007 Oct;22(10):1165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma.
  • BACKGROUND AND AIMS: Although the role of transforming growth factor beta (TGFbeta) 1 and metalloproteinase-9 (MMP-9) is well documented in colorectal cancer (CC), there is a little evidence supporting its role in early carcinogenesis.
  • PATIENT/METHODS: The study group comprised 50 patients with colorectal polyps and 33 patients with CC.
  • RESULTS: Among 62 adenomas, 33 high-grade dysplasia (HGD) and 29 low-grade dysplasia (LGD) had been detected.
  • CONCLUSION: The increased expression of TGFbeta1, MMP-9 observed in colorectal adenomas seems to be related to the grade of dysplasia.
  • We assume that overexpression of TGFbeta1, MMP-9 represent an early event in colorectal carcinogenesis and may possibly have the prognostic value.
  • [MeSH-major] Adenoma / metabolism. Colorectal Neoplasms / metabolism. Matrix Metalloproteinase 9 / metabolism. Transforming Growth Factor beta1 / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Sep;72(3):575-82 [7669564.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):175-82 [10981868.001]
  • [Cites] Surgery. 2003 May;133(5):568-79 [12773985.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1488-95 [7926512.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):239-46 [1646457.001]
  • [Cites] Future Oncol. 2006 Dec;2(6):743-63 [17155901.001]
  • [Cites] Clin Exp Metastasis. 1993 Mar;11(2):183-9 [8444010.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):3872-7 [2162246.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):607-14 [10080606.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 7;85(7):574-8 [8384265.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):753-8 [8795578.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Jan 16;158(1):228-34 [2536277.001]
  • [Cites] Pathol Oncol Res. 1999;5(4):273-9 [10607921.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1495-502 [9836483.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3366-70 [8764135.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1741-5 [14534689.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):194-205 [10389996.001]
  • [Cites] Carcinogenesis. 1999 May;20(5):749-55 [10334190.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3245-9 [15929175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Oncol Rep. 2005 Jan;13(1):115-20 [15583811.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] J Clin Gastroenterol. 1992 Dec;15(4):317-20 [1294637.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):24-9 [11869009.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):224-33 [11166150.001]
  • [Cites] Dis Colon Rectum. 1997 Mar;40(3):322-5 [9118748.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] J Neurooncol. 1994;18(2):105-9 [7964973.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Mol Carcinog. 2006 Oct;45(10):786-94 [16921482.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Sep;16(3):281-8 [9387902.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1255-64 [8918435.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):674-8 [12174377.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] APMIS. 1997 Sep;105(9):730-4 [9350218.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):137-9 [8318404.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89 [15588763.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1002-7 [15931661.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):696-700 [2661411.001]
  • [Cites] Oncogene. 1998 Oct 15;17 (15):1969-78 [9788440.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3359-65 [8764134.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2501-5 [2684387.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):50-6 [8014015.001]
  • [Cites] Adv Cancer Res. 1997;71:165-207 [9111866.001]
  • [Cites] Neoplasma. 2005;52(5):420-4 [16151588.001]
  • (PMID = 17394006.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Transforming Growth Factor beta1; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


92. de Bruin JH, Kievit W, Ligtenberg MJ, Nagengast FM, Adang EM, Ruers TJ, Kleibeuker JH, Sijmons RH, van Krieken JH, Hoogerbrugge N: [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability]. Ned Tijdschr Geneeskd; 2005 Aug 6;149(32):1792-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability].
  • [Transliterated title] Meer opsporing van erfelijke darmkanker met onderzoek op microsatellietinstabiliteit bij door de patholoog geselecteerde patiënten met een colon-rectumcarcinoom.
  • OBJECTIVE: To determine whether an investigation of microsatellite instability (MSI) in patients with colorectal carcinoma that have been selected by the pathologist could increase the number of detected families with hereditary non-polyposis colorectal carcinoma (HNPCC).
  • METHOD: Pathologists selected patients with a newly diagnosed colorectal carcinoma for MSI analysis of their tumour tissue if they met one of the following four criteria: (a) colorectal carcinoma diagnosed below 50 years of age;.
  • (b) a second colorectal carcinoma;.
  • (c) a combination of colorectal carcinoma and another HNPCC-related cancer;.
  • (d) colorectal adenoma with high-grade dysplasia diagnosed below 40 years of age.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Germ-Line Mutation. Microsatellite Repeats
  • [MeSH-minor] Adult. Colorectal Neoplasms / diagnosis. Diagnosis, Differential. Female. Genetic Testing. Genomic Instability. Humans. Male. Middle Aged. Netherlands. Pedigree. Predictive Value of Tests. Prospective Studies


93. Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS: Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma. J Natl Cancer Inst; 2005 Mar 16;97(6):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variants in the UGT1A6 enzyme, aspirin use, and the risk of colorectal adenoma.
  • To determine whether polymorphisms in the UGT1A6 enzyme modulate the protective benefit of regular aspirin use on colorectal adenoma, we conducted a prospective, nested case-control study of 1062 women who provided blood specimens and detailed data on aspirin use before undergoing lower endoscopy.
  • Although UGT1A6 genotype was not associated with overall adenoma risk (multivariable odds ratio [OR] = 1.10, 95% confidence interval [CI] = 0.85 to 1.41), functional variant genotypes statistically significantly modified the effect of aspirin on adenoma (P(interaction) = .02).
  • Among the 616 women with variant genotypes, regular use of aspirin (two or more standard tablets per week) was associated with a decreased risk of adenoma (multivariable OR for adenoma = 0.66 [95% CI = 0.45 to 0.95], OR = 0.63 [95% CI = 0.43 to 0.91] for 0.5-7 standard tablets per week and OR = 0.41 [95% CI = 0.24 to 0.71] for more than 7 tablets per week; P(trend) = .001).
  • These results were consistent among women with advanced adenomas (P(interaction) = .003).
  • Thus, functional polymorphisms in the UGT1A6 enzyme statistically significantly modify the effect of aspirin on colorectal neoplasia, and certain subsets of the population, defined by genotype, may obtain differential benefit from aspirin chemoprevention.
  • [MeSH-major] Adenoma / genetics. Adenoma / prevention & control. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Aspirin / administration & dosage. Colorectal Neoplasms / genetics. Colorectal Neoplasms / prevention & control. Glucuronosyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827850869 for PMID:15770010 [PharmGKB] .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Natl Cancer Inst. 2005 Aug 17;97(16):1227
  • (PMID = 15770010.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 09001-27; United States / NCI NIH HHS / CA / CA 55075; United States / NCI NIH HHS / CA / CA 87969; United States / NHLBI NIH HHS / HL / HL 34594
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; EC 2.4.1.- / UDP-glucuronosyltransferase, UGT1A6; EC 2.4.1.17 / Glucuronosyltransferase; R16CO5Y76E / Aspirin
  •  go-up   go-down


94. Fedirko V, Bostick RM, Flanders WD, Long Q, Shaukat A, Rutherford RE, Daniel CR, Cohen V, Dash C: Effects of vitamin D and calcium supplementation on markers of apoptosis in normal colon mucosa: a randomized, double-blind, placebo-controlled clinical trial. Cancer Prev Res (Phila); 2009 Mar;2(3):213-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further clarify and/or develop calcium and vitamin D as chemopreventive agents against colorectal cancer in humans, understand the mechanisms by which these agents reduce risk for the disease, and develop "treatable" biomarkers of risk for colorectal cancer, we conducted a pilot, randomized, double-blind, placebo-controlled, 2 x 2 factorial clinical trial to test the effects of calcium and vitamin D3, alone and in combination on markers of apoptosis, in the normal colorectal mucosa.
  • Ninety-two men and women with at least one pathology-confirmed colorectal adenoma were treated with 2.0 g/d calcium or 800 IU/d vitamin D3, alone or in combination, versus placebo over 6 months.
  • Overall expression and colorectal crypt distributions of Bcl-2 (an apoptosis inhibitor) and Bax (an apoptosis promoter) in biopsies of normal-appearing rectal mucosa were detected by automated immunohistochemistry and quantified by image analysis.
  • Overall, these preliminary results suggest that calcium and vitamin D, individually or together, may enhance apoptosis in the normal human colorectal epithelium, and the strongest treatment effects may be vitamin D related and in the upper sections of the colorectal crypts.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CHOLECALCIFEROL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Pharm Des. 2000 May;6(7):717-32 [10828303.001]
  • [Cites] Gut. 2001 Feb;48(2):238-46 [11156647.001]
  • [Cites] Oncol Rep. 2001 Jul-Aug;8(4):893-7 [11410805.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1267-74 [11751444.001]
  • [Cites] Ann N Y Acad Sci. 2001 Dec;952:73-87 [11795445.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):437-46 [11904316.001]
  • [Cites] Food Chem Toxicol. 2002 Jun;40(6):801-8 [11983275.001]
  • [Cites] Cancer Causes Control. 2002 Apr;13(3):213-20 [12020102.001]
  • [Cites] Nutr Cancer. 2001;41(1-2):150-5 [12094618.001]
  • [Cites] J Natl Cancer Inst. 2003 Jun 18;95(12):896-905 [12813173.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):546-52 [15066918.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):291-5 [15200153.001]
  • [Cites] J Natl Cancer Inst. 1984 Jun;72(6):1323-5 [6587152.001]
  • [Cites] Carcinogenesis. 1988 Jan;9(1):187-90 [2826033.001]
  • [Cites] Am J Epidemiol. 1988 Jan;127(1):188-99 [3337073.001]
  • [Cites] Carcinogenesis. 1989 Apr;10(4):647-9 [2702712.001]
  • [Cites] Cancer Res. 1991 Oct 15;51(20):5608-13 [1913678.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7 Suppl):2067s-2070s [1544142.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] J Nutr. 1993 Jan;123(1):144-52 [8421225.001]
  • [Cites] Epidemiol Rev. 1993;15(2):499-545 [8174669.001]
  • [Cites] Calcif Tissue Int. 1995 Jun;56(6):518-20 [7648477.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 6;87(17):1307-15 [7658483.001]
  • [Cites] Cancer Lett. 1995 Oct 20;97(1):99-106 [7585485.001]
  • [Cites] Clin Chem. 1996 Apr;42(4):586-92 [8605676.001]
  • [Cites] Methods Enzymol. 1997;282:174-86 [9330287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):931-42 [9367067.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Mar;7(3):221-5 [9521437.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Int J Oncol. 1999 May;14(5):979-85 [10200351.001]
  • [Cites] Am J Clin Nutr. 1999 May;69(5):842-56 [10232622.001]
  • [Cites] Gut. 1999 Jul;45(1):45-50 [10369703.001]
  • [Cites] Calcif Tissue Int. 1999 Oct;65(4):295-306 [10485982.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1358-65 [15531687.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3463S-3471S [15570055.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):493-8 [15695391.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):525-8 [15734982.001]
  • [Cites] Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28 [15951480.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):137-44 [15880532.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):287-96 [16353199.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Feb;57(2):107-21 [16326109.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1178-86 [17379616.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(1):CD003548 [18254022.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2304-12 [10786699.001]
  • [CommentIn] Cancer Prev Res (Phila). 2009 Mar;2(3):197-9 [19258545.001]
  • (PMID = 19258546.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104637-01; United States / NCI NIH HHS / CA / R01 CA104637; United States / NCI NIH HHS / CA / R01 CA104637-01
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 1406-16-2 / Vitamin D; 1C6V77QF41 / Cholecalciferol; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS120314; NLM/ PMC2712935
  •  go-up   go-down


95. Wolpin BM, Wei EK, Ng K, Meyerhardt JA, Chan JA, Selhub J, Giovannucci EL, Fuchs CS: Prediagnostic plasma folate and the risk of death in patients with colorectal cancer. J Clin Oncol; 2008 Jul 1;26(19):3222-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediagnostic plasma folate and the risk of death in patients with colorectal cancer.
  • PURPOSE: Although previous studies have demonstrated an inverse relationship between folate intake and colorectal cancer risk, a recent trial suggests that supplemental folic acid may accelerate tumorigenesis among patients with a history of colorectal adenoma.
  • Therefore, high priority has been given to research investigating the influence of folate on cancer progression in patients with colorectal cancer.
  • PATIENTS AND METHODS: To investigate whether prediagnostic levels of plasma folate are associated with colorectal cancer-specific and overall mortality, we performed a prospective, nested observational study within two large US cohorts: the Nurses' Health Study and Health Professionals Follow-Up Study.
  • We measured folate levels among 301 participants who developed colorectal cancer 2 or more years after their plasma was collected and compared participants using Cox proportional hazards models by quintile of plasma folate.
  • RESULTS: Higher levels of plasma folate were not associated with an increased risk of colorectal cancer-specific or overall mortality.
  • Compared with participants in the lowest quintile of plasma folate, those in the highest quintile experienced a multivariable-adjusted hazard ratio for colorectal cancer-specific mortality of 0.42 (95% CI, 0.20 0.88) and overall mortality of 0.46 (95% CI, 0.24 0.88).
  • When the analysis was limited to participants whose plasma was collected within 5 years of cancer diagnosis, no detrimental effect of high plasma folate was noted.
  • CONCLUSION: In two large prospective cohorts, higher prediagnostic levels of plasma folate were not associated with an increased risk of colorectal cancer-specific or overall mortality.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jun 6;297(21):2408-9 [17551134.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2350S-2355S [12163691.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):511-9 [15066913.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):339-49 [15286019.001]
  • [Cites] Nutr Rev. 2004 Jun;62(6 Pt 2):S35-9 [15298446.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3766-75 [15365073.001]
  • [Cites] Br J Nutr. 2004 Sep;92(3):489-96 [15469653.001]
  • [Cites] Am J Epidemiol. 1994 Dec 1;140(11):1016-9 [7985649.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):487-94 [8827351.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1098-102 [9067278.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1917-22 [10206314.001]
  • [Cites] N Engl J Med. 1999 May 13;340(19):1449-54 [10320382.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):825-8 [15499620.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):476-87 [15689586.001]
  • [Cites] Support Care Cancer. 2005 Nov;13(11):912-9 [15856334.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):189-93 [16492904.001]
  • [Cites] Gut. 2006 Oct;55(10):1461-6 [16638790.001]
  • [Cites] Gut. 2006 Oct;55(10):1387-9 [16966698.001]
  • [Cites] Am J Clin Nutr. 2007 Jan;85(1):277S-279S [17209209.001]
  • [Cites] Mol Nutr Food Res. 2007 Mar;51(3):267-92 [17295418.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1325-9 [17626997.001]
  • (PMID = 18591557.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108341; United States / NCI NIH HHS / CA / R01 CA118553; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / T32 CA009172; United States / NCI NIH HHS / CA / R03 CA108341; United States / NCI NIH HHS / CA / CA118553; United States / NCI NIH HHS / CA / CA09001; United States / NCI NIH HHS / CA / T32 CA009001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  • [Other-IDs] NLM/ NIHMS557427; NLM/ PMC3962289
  •  go-up   go-down


96. Kim S, Baron JA, Mott LA, Burke CA, Church TR, McKeown-Eyssen GE, Cole BF, Haile RW, Sandler RS: Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States). Cancer Causes Control; 2006 Dec;17(10):1299-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States).
  • Aspirin, which may affect the levels of these cytokines, has been shown in randomized controlled trials to decrease the risk of colorectal adenomas.
  • Data were available from the Aspirin/Folate Polyp Prevention Study, a randomized controlled trial of aspirin and folic acid to prevent recurrent colorectal adenomas.
  • For the analysis of the effect of aspirin on the recurrence of colorectal adenoma by BMI, we computed risk ratios for aspirin versus placebo within the three BMI strata using a modified Poisson model.
  • Overall the risk reduction of adenomas with a daily dose of 325 mg aspirin was greater among subjects with higher BMI.
  • Among obese subjects the risk ratio (RR) for advanced adenomas compared with placebo was 0.44 (95% CI 0.17-1.10), versus RR = 1.23 (95% CI 0.55-2.77) among those with normal weight.
  • However, 81 mg aspirin daily did not interact with BMI to modify the risk of adenomas in such a fashion.
  • [MeSH-major] Adenomatous Polyps / prevention & control. Aspirin / pharmacology. Body Mass Index. Colorectal Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17111262.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK34987; United States / NCI NIH HHS / CA / R01 CA59005; United States / NCRR NIH HHS / RR / RR000046
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] R16CO5Y76E / Aspirin
  •  go-up   go-down


97. Ji JS, Choi KY, Lee WC, Lee BI, Park SH, Choi H, Kim BW, Chae HS, Park YM, Park YJ: Endoscopic and histopathologic predictors of recurrence of colorectal adenoma on lowering the miss rate. Korean J Intern Med; 2009 Sep;24(3):196-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic and histopathologic predictors of recurrence of colorectal adenoma on lowering the miss rate.
  • BACKGROUND/AIMS: Although colorectal adenoma is reported to recur frequently, this may result from missing it at baseline.
  • This study evaluated the recurrence rate prospectively and clinical predictors of recurrence in colorectal adenoma after lowering the miss rate.
  • METHODS: The study population comprised 128 patients who underwent baseline colonoscopy with resection of colorectal adenomas.
  • Thirty patients had a recurrent adenoma, for a recurrence rate of 23.4%.
  • Patients with three or four adenomas at baseline colonoscopy had a two-fold greater risk than those with one adenoma (hazard ratio, 2.44; 95% CI, 1.11-5.35).
  • Patients with advanced adenoma had a two-fold greater risk than those with no advanced adenoma (hazard ratio, 2.88; 95% CI, 1.40-5.95).
  • In multivariate analysis, only the presence of three or four adenomas independently predicted the recurrence of adenoma (hazard ratio, 3.19; 95% CI, 1.04-9.79).
  • CONCLUSIONS: The recurrence rate of colorectal adenoma corrected by lowering the miss rate was lower than reported rates.
  • The presence of multiple adenomas on initial colonoscopy was an important predictor of recurrence.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy. Colorectal Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Colonic Polyps / diagnosis. Colonic Polyps / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):433-7 [10744815.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Gastroenterology. 2001 Apr;120(5):1077-83 [11266371.001]
  • [Cites] Gut. 2001 Jun;48(6):812-5 [11358901.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1524-9 [12094877.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):323-33 [14991494.001]
  • [Cites] Ann Surg. 1975 Oct;182(4):511-5 [1180587.001]
  • [Cites] Cancer. 1978 Dec;42(6):2839-48 [728878.001]
  • [Cites] Cancer. 1979 May;43(5):1847-57 [445371.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):819-25 [7055790.001]
  • [Cites] Endoscopy. 1985 Sep;17(5):175-81 [4054062.001]
  • [Cites] Scand J Gastroenterol. 1987 Sep;22(7):833-41 [3672041.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):64-7 [1796931.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):3-6 [1994603.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):941-5 [1858757.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • [Cites] Scand J Gastroenterol. 1993 Oct;28(10):869-74